{
    "PMC8668943_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 acquisition": "reduced odds",
                        "Odds Ratio (OR)": "0.29",
                        "Confidence Interval (CI)": "0.12-0.71",
                        "P-value": "0.007",
                        "Bonferroni corrected P-value (PBonf)": "0.112",
                        "Dataset": "Perinatal HIV-1 acquisition",
                        "Adjustment factors": "None"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": "[0.29]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "1 copy",
                        "Bonferroni corrected P-value": "0.112"
                    },
                    "measures": "[Univariate OR, 95% CI, P-value]",
                    "outcomes": "[0.29, (0.12-0.71), 0.007]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 acquisition": "retained significance",
                        "Odds Ratio (AOR)": "0.37",
                        "Confidence Interval (CI)": "0.15-0.90",
                        "P-value": "0.029",
                        "Bonferroni corrected P-value (PBonf)": "0.464",
                        "Dataset": "Perinatal HIV-1 acquisition",
                        "Adjustment factors": "Birthweight and FCGR2C genotypes"
                    },
                    "measures": "[Adjusted Odds Ratio]",
                    "outcomes": "[0.37]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "1 copy",
                        "Bonferroni corrected P-value": "0.464"
                    },
                    "measures": "[Adjusted OR, 95%CI, P-value]",
                    "outcomes": "[0.37 (0.15-0.90), 0.029]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "FCGR2C gene copy": "single copy",
                        "Association": "reduced odds of HIV-1 acquisition",
                        "Dataset": "Perinatal HIV-1 acquisition"
                    },
                    "measures": "[Association]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "2 copies"
                    },
                    "measures": "[Univariate OR, 95% CI, P-value]",
                    "outcomes": "[Ref, Ref, Ref]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "FCGR2C gene copy": "single copy",
                        "Association": "reduced odds of HIV-1 acquisition",
                        "Dataset": "Perinatal HIV-1 acquisition"
                    },
                    "measures": "[Association]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "\u22653 copies"
                    },
                    "measures": "[Univariate OR, 95% CI, P-value]",
                    "outcomes": "[0.99, (0.63-1.57), 0.978]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "FCGR2C gene copy": "single copy",
                        "Association": "reduced odds of HIV-1 acquisition",
                        "Dataset": "Perinatal HIV-1 acquisition"
                    },
                    "measures": "[Association]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "\u22653 copies"
                    },
                    "measures": "[Adjusted OR, 95% CI, P-value]",
                    "outcomes": "[0.74, (0.43-1.27), 0.275]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "FCGR2C gene copy": "\u22653 copies",
                        "Odds Ratio (OR)": "0.99",
                        "Confidence Interval (CI)": "0.63-1.57",
                        "P-value": "0.978",
                        "Bonferroni corrected P-value (PBonf)": "0.275",
                        "Dataset": "Perinatal HIV-1 acquisition",
                        "Adjustment factors": "None"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": "[0.99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "2 copies"
                    },
                    "measures": "[Univariate OR, 95% CI, P-value]",
                    "outcomes": "[Ref, Ref, Ref]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "FCGR2C gene copy": "\u22653 copies",
                        "Odds Ratio (OR)": "0.99",
                        "Confidence Interval (CI)": "0.63-1.57",
                        "P-value": "0.978",
                        "Bonferroni corrected P-value (PBonf)": "0.275",
                        "Dataset": "Perinatal HIV-1 acquisition",
                        "Adjustment factors": "None"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": "[0.99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "\u22653 copies"
                    },
                    "measures": "[Univariate OR, 95% CI, P-value]",
                    "outcomes": "[0.99, (0.63-1.57), 0.978]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "FCGR2C gene copy": "\u22653 copies",
                        "Odds Ratio (OR)": "0.99",
                        "Confidence Interval (CI)": "0.63-1.57",
                        "P-value": "0.978",
                        "Bonferroni corrected P-value (PBonf)": "0.275",
                        "Dataset": "Perinatal HIV-1 acquisition",
                        "Adjustment factors": "None"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": "[0.99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "\u22653 copies"
                    },
                    "measures": "[Adjusted OR, 95% CI, P-value]",
                    "outcomes": "[0.74, (0.43-1.27), 0.275]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "FCGR2C gene copy": "\u22653 copies",
                        "Odds Ratio (AOR)": "0.74",
                        "Confidence Interval (CI)": "0.43-1.27",
                        "P-value": "0.275",
                        "Bonferroni corrected P-value (PBonf)": "0.275",
                        "Dataset": "Perinatal HIV-1 acquisition",
                        "Adjustment factors": "Birthweight and FCGR2C genotypes"
                    },
                    "measures": "[Adjusted Odds Ratio]",
                    "outcomes": "[0.74]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "2 copies"
                    },
                    "measures": "[Univariate OR, 95% CI, P-value]",
                    "outcomes": "[Ref, Ref, Ref]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "FCGR2C gene copy": "\u22653 copies",
                        "Odds Ratio (AOR)": "0.74",
                        "Confidence Interval (CI)": "0.43-1.27",
                        "P-value": "0.275",
                        "Bonferroni corrected P-value (PBonf)": "0.275",
                        "Dataset": "Perinatal HIV-1 acquisition",
                        "Adjustment factors": "Birthweight and FCGR2C genotypes"
                    },
                    "measures": "[Adjusted Odds Ratio]",
                    "outcomes": "[0.74]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "\u22653 copies"
                    },
                    "measures": "[Univariate OR, 95% CI, P-value]",
                    "outcomes": "[0.99, (0.63-1.57), 0.978]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "FCGR2C gene copy": "\u22653 copies",
                        "Odds Ratio (AOR)": "0.74",
                        "Confidence Interval (CI)": "0.43-1.27",
                        "P-value": "0.275",
                        "Bonferroni corrected P-value (PBonf)": "0.275",
                        "Dataset": "Perinatal HIV-1 acquisition",
                        "Adjustment factors": "Birthweight and FCGR2C genotypes"
                    },
                    "measures": "[Adjusted Odds Ratio]",
                    "outcomes": "[0.74]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "\u22653 copies"
                    },
                    "measures": "[Adjusted OR, 95% CI, P-value]",
                    "outcomes": "[0.74, (0.43-1.27), 0.275]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 5,
        "total_ground_truth_claims": 5,
        "number_of_matches": 3
    },
    "PMC5817808_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Feeding Mode": "Exclusive breast feeding",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "2.45%",
                        "Unadjusted HR": "1.35 [0.52-3.49]",
                        "Unadjusted HR p-value": "0.54"
                    },
                    "measures": "[0.52-3.49]",
                    "outcomes": [
                        "[Unadjusted Hazard Ratio]",
                        "[1.35]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.35 [0.52-3.49]",
                        "0.54"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Feeding Mode": "Exclusive breast feeding",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "2.45%",
                        "Adjusted HR": "1.16 [0.44-3.08]",
                        "Adjusted HR p-value": "0.76"
                    },
                    "measures": "[0.44-3.08]",
                    "outcomes": [
                        "[Adjusted Hazard Ratio]",
                        "[1.16]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.16 [0.44-3.08]",
                        "0.76"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Feeding Mode": "Mixed feeding",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "13.33%",
                        "Unadjusted HR": "0.31 [0.04-2.42]",
                        "Unadjusted HR p-value": "0.26"
                    },
                    "measures": "[0.04-2.42]",
                    "outcomes": [
                        "[Unadjusted Hazard Ratio]",
                        "[0.31]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Feeding Mode": "Mixed feeding",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "13.33%",
                        "Unadjusted HR": "0.31 [0.04-2.42]",
                        "Unadjusted HR p-value": "0.26"
                    },
                    "measures": "[0.04-2.42]",
                    "outcomes": [
                        "[Unadjusted Hazard Ratio]",
                        "[0.31]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Feeding Mode": "Mixed feeding",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "13.33%",
                        "Unadjusted HR": "0.31 [0.04-2.42]",
                        "Unadjusted HR p-value": "0.26"
                    },
                    "measures": "[0.04-2.42]",
                    "outcomes": [
                        "[Unadjusted Hazard Ratio]",
                        "[0.31]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.04-2.42]",
                        "0.26"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Feeding Mode": "Mixed feeding",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "13.33%",
                        "Adjusted HR": "0.44 [0.053-3.74]",
                        "Adjusted HR p-value": "0.45"
                    },
                    "measures": "[0.053-3.74]",
                    "outcomes": [
                        "[Adjusted Hazard Ratio]",
                        "[0.44]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Feeding Mode": "Mixed feeding",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "13.33%",
                        "Adjusted HR": "0.44 [0.053-3.74]",
                        "Adjusted HR p-value": "0.45"
                    },
                    "measures": "[0.053-3.74]",
                    "outcomes": [
                        "[Adjusted Hazard Ratio]",
                        "[0.44]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Feeding Mode": "Mixed feeding",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "13.33%",
                        "Adjusted HR": "0.44 [0.053-3.74]",
                        "Adjusted HR p-value": "0.45"
                    },
                    "measures": "[0.053-3.74]",
                    "outcomes": [
                        "[Adjusted Hazard Ratio]",
                        "[0.44]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.44 [0.053-3.74]",
                        "0.45"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Feeding Mode": "Exclusive replacement feeding",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Unadjusted HR": "Ref",
                        "Unadjusted HR p-value": "Ref"
                    },
                    "measures": "[Unadjusted Hazard Ratio]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Status": "Positive",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Unadjusted HR": "0.31 [0.11-0.90]",
                        "Unadjusted HR p-value": "0.032"
                    },
                    "measures": "[0.11-0.90]",
                    "outcomes": [
                        "[Unadjusted Hazard Ratio]",
                        "[0.31]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Status": "Positive",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Unadjusted HR": "0.31 [0.11-0.90]",
                        "Unadjusted HR p-value": "0.032"
                    },
                    "measures": "[0.11-0.90]",
                    "outcomes": [
                        "[Unadjusted Hazard Ratio]",
                        "[0.31]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.11-0.90]",
                        "0.032"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Status": "Positive",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Adjusted HR": "0.30 [0.08-1.11]",
                        "Adjusted HR p-value": "0.071"
                    },
                    "measures": "[0.08-1.11]",
                    "outcomes": [
                        "[Adjusted Hazard Ratio]",
                        "[0.30]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Status": "Positive",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Adjusted HR": "0.30 [0.08-1.11]",
                        "Adjusted HR p-value": "0.071"
                    },
                    "measures": "[0.08-1.11]",
                    "outcomes": [
                        "[Adjusted Hazard Ratio]",
                        "[0.30]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.30 [0.08-1.11]",
                        "0.071"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Birth weight": ">=2500 g",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Unadjusted HR": "0.88 [0.34-2.28]",
                        "Unadjusted HR p-value": "0.80"
                    },
                    "measures": "[0.34-2.28]",
                    "outcomes": [
                        "[Unadjusted Hazard Ratio]",
                        "[0.88]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Birth weight": ">=2500 g",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Unadjusted HR": "0.88 [0.34-2.28]",
                        "Unadjusted HR p-value": "0.80"
                    },
                    "measures": "[0.34-2.28]",
                    "outcomes": [
                        "[Unadjusted Hazard Ratio]",
                        "[0.88]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Birth weight": ">=2500 g",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Unadjusted HR": "0.88 [0.34-2.28]",
                        "Unadjusted HR p-value": "0.80"
                    },
                    "measures": "[0.34-2.28]",
                    "outcomes": [
                        "[Unadjusted Hazard Ratio]",
                        "[0.88]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Birth weight": ">=2500 g",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Unadjusted HR": "0.88 [0.34-2.28]",
                        "Unadjusted HR p-value": "0.80"
                    },
                    "measures": "[0.34-2.28]",
                    "outcomes": [
                        "[Unadjusted Hazard Ratio]",
                        "[0.88]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.70 [0.16-2.96]",
                        "0.63"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Birth weight": ">=2500 g",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Unadjusted HR": "0.88 [0.34-2.28]",
                        "Unadjusted HR p-value": "0.80"
                    },
                    "measures": "[0.34-2.28]",
                    "outcomes": [
                        "[Unadjusted Hazard Ratio]",
                        "[0.88]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.93 [0.21-4.12]",
                        "0.92"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Birth weight": ">=2500 g",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Unadjusted HR": "0.88 [0.34-2.28]",
                        "Unadjusted HR p-value": "0.80"
                    },
                    "measures": "[0.34-2.28]",
                    "outcomes": [
                        "[Unadjusted Hazard Ratio]",
                        "[0.88]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": "< 2500 g"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Birth weight": ">=2500 g",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Unadjusted HR": "0.88 [0.34-2.28]",
                        "Unadjusted HR p-value": "0.80"
                    },
                    "measures": "[0.34-2.28]",
                    "outcomes": [
                        "[Unadjusted Hazard Ratio]",
                        "[0.88]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": "< 2500 g"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Birth weight": ">=2500 g",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Unadjusted HR": "0.88 [0.34-2.28]",
                        "Unadjusted HR p-value": "0.80"
                    },
                    "measures": "[0.34-2.28]",
                    "outcomes": [
                        "[Unadjusted Hazard Ratio]",
                        "[0.88]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Global Schoenfeld residuals test",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program"
                    },
                    "measures": [
                        "p-value"
                    ],
                    "outcomes": [
                        "0.23"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Birth weight": ">=2500 g",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Adjusted HR": "0.93 [0.21-4.12]",
                        "Adjusted HR p-value": "0.92"
                    },
                    "measures": "[0.21-4.12]",
                    "outcomes": [
                        "[Adjusted Hazard Ratio]",
                        "[0.93]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Birth weight": ">=2500 g",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Adjusted HR": "0.93 [0.21-4.12]",
                        "Adjusted HR p-value": "0.92"
                    },
                    "measures": "[0.21-4.12]",
                    "outcomes": [
                        "[Adjusted Hazard Ratio]",
                        "[0.93]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Birth weight": ">=2500 g",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Adjusted HR": "0.93 [0.21-4.12]",
                        "Adjusted HR p-value": "0.92"
                    },
                    "measures": "[0.21-4.12]",
                    "outcomes": [
                        "[Adjusted Hazard Ratio]",
                        "[0.93]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Birth weight": ">=2500 g",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Adjusted HR": "0.93 [0.21-4.12]",
                        "Adjusted HR p-value": "0.92"
                    },
                    "measures": "[0.21-4.12]",
                    "outcomes": [
                        "[Adjusted Hazard Ratio]",
                        "[0.93]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.70 [0.16-2.96]",
                        "0.63"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Birth weight": ">=2500 g",
                        "Study Population": "HIV exposed infants",
                        "Hospital": "Essos hospital center",
                        "Program": "PMTCT",
                        "Survival Period": "24 months",
                        "Mortality Rate": "Ref",
                        "Adjusted HR": "0.93 [0.21-4.12]",
                        "Adjusted HR p-value": "0.92"
                    },
                    "measures": "[0.21-4.12]",
                    "outcomes": [
                        "[Adjusted Hazard Ratio]",
                        "[0.93]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.93 [0.21-4.12]",
                        "0.92"
                    ]
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 9,
        "total_ground_truth_claims": 15,
        "number_of_matches": 8
    },
    "PMC5574138_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Covariate": "Length of follow-up",
                        "Estimate": "\u22120.0138",
                        "Standard Error": "0.0666",
                        "Confidence Interval": "(\u22120.1322\u20130.1046)",
                        "Analysis Type": "Meta-regression",
                        "Dependent Variable": "Study",
                        "Independent Variables": "Length of follow-up, Median CD4 cell counts, Median age, Year of publication, Proportion of female"
                    },
                    "measures": "[Estimate]",
                    "outcomes": "[\u22120.0138]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Covariate": "Length of follow-up",
                        "Method": "Meta-regression"
                    },
                    "measures": "[Estimate, S.E, 95% CI]",
                    "outcomes": "[-0.0138, 0.0666, (-0.1322\u20130.1046)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Covariate": "Median CD4 count",
                        "Estimate": "\u22120.0034",
                        "Standard Error": "0.0066",
                        "Confidence Interval": "(\u22120.0150\u20130.0079)",
                        "Analysis Type": "Meta-regression",
                        "Dependent Variable": "Study",
                        "Independent Variables": "Length of follow-up, Median CD4 cell counts, Median age, Year of publication, Proportion of female"
                    },
                    "measures": "[Estimate]",
                    "outcomes": "[\u22120.0034]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Covariate": "Median CD4 count",
                        "Method": "Meta-regression"
                    },
                    "measures": "[Estimate, S.E, 95% CI]",
                    "outcomes": "[-0.0034, 0.0066, (-0.0150\u20130.0079)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Covariate": "Median age",
                        "Estimate": "0.0415",
                        "Standard Error": "0.0503",
                        "Confidence Interval": "(\u22120.1013\u20130.0755)",
                        "Analysis Type": "Meta-regression",
                        "Dependent Variable": "Study",
                        "Independent Variables": "Length of follow-up, Median CD4 cell counts, Median age, Year of publication, Proportion of female"
                    },
                    "measures": "[Estimate]",
                    "outcomes": "[0.0415]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Covariate": "Median age",
                        "Method": "Meta-regression"
                    },
                    "measures": "[Estimate, S.E, 95% CI]",
                    "outcomes": "[0.0415, 0.0503, (-0.1013\u20130.0755)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Covariate": "Year of publication",
                        "Estimate": "0.0637",
                        "Standard Error": "0.0815",
                        "Confidence Interval": "(\u22120.1736\u20130.0980)",
                        "Analysis Type": "Meta-regression",
                        "Dependent Variable": "Study",
                        "Independent Variables": "Length of follow-up, Median CD4 cell counts, Median age, Year of publication, Proportion of female"
                    },
                    "measures": "[Estimate]",
                    "outcomes": "[0.0637]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Covariate": "Year of publication",
                        "Method": "Meta-regression"
                    },
                    "measures": "[Estimate, S.E, 95% CI]",
                    "outcomes": "[0.0637, 0.0815, (-0.1736\u20130.0980)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Covariate": "Proportion of female",
                        "Estimate": "\u22120.5305",
                        "Standard Error": "1.4575",
                        "Confidence Interval": "(\u22123.6792\u20132.6183)",
                        "Analysis Type": "Meta-regression",
                        "Dependent Variable": "Study",
                        "Independent Variables": "Length of follow-up, Median CD4 cell counts, Median age, Year of publication, Proportion of female"
                    },
                    "measures": "[Estimate]",
                    "outcomes": "[\u22120.5305]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Covariate": "Female proportion",
                        "Method": "Meta-regression"
                    },
                    "measures": "[Estimate, S.E, 95% CI]",
                    "outcomes": "[-0.5305, 1.4575, (-3.6792\u20132.6183)]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 9,
        "total_ground_truth_claims": 5,
        "number_of_matches": 5
    },
    "PMC4794224_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "97%",
                        "966"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL3"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "72%",
                        "719"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL4"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL5"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "55%",
                        "547"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL2*004"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "3%",
                        "31"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL2*001/2/3/5"
                    },
                    "measures": [
                        "Positive Frequency, N"
                    ],
                    "outcomes": [
                        "55%",
                        "544"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DP1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "97%",
                        "964"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "55%",
                        "548"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS2"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "59%",
                        "581"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS3"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "40%",
                        "401"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS4"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS5"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "28%",
                        "281"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DL1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "94%",
                        "929"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DL2"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DL3"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Cent"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DS1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "36%",
                        "354"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "97%",
                        "966"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL3"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "72%",
                        "719"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL4"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL5"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "55%",
                        "547"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL2*004"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "3%",
                        "31"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL2*001/2/3/5"
                    },
                    "measures": [
                        "Positive Frequency, N"
                    ],
                    "outcomes": [
                        "55%",
                        "544"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DP1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "97%",
                        "964"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "55%",
                        "548"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS2"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "59%",
                        "581"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS3"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "40%",
                        "401"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS4"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS5"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "28%",
                        "281"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DL1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "94%",
                        "929"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DL2"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DL3"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Cohort": "studied cohort",
                        "Table": "Table 2",
                        "Context": "Distribution of KIR alleles",
                        "Metric": "Frequency of KIR alleles",
                        "KIR Genotypes": "Tel"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DS1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "36%",
                        "354"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR2DL1",
                        "Value": "97%",
                        "Metric": "Frequency",
                        "Outcome": "966"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "97%",
                        "966"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR2DL3",
                        "Value": "72%",
                        "Metric": "Frequency",
                        "Outcome": "719"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL3"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "72%",
                        "719"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR2DL4",
                        "Value": "100%",
                        "Metric": "Frequency",
                        "Outcome": "993"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL4"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR2DL5",
                        "Value": "55%",
                        "Metric": "Frequency",
                        "Outcome": "547"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL5"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "55%",
                        "547"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR2DL2*004",
                        "Value": "3%",
                        "Metric": "Frequency",
                        "Outcome": "31"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL2*004"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "3%",
                        "31"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR2DL2*001/2/3/5",
                        "Value": "55%",
                        "Metric": "Frequency",
                        "Outcome": "544"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL2*001/2/3/5"
                    },
                    "measures": [
                        "Positive Frequency, N"
                    ],
                    "outcomes": [
                        "55%",
                        "544"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR2DP1",
                        "Value": "97%",
                        "Metric": "Frequency",
                        "Outcome": "964"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DP1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "97%",
                        "964"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR2DS1",
                        "Value": "55%",
                        "Metric": "Frequency",
                        "Outcome": "548"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "55%",
                        "548"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR2DS2",
                        "Value": "59%",
                        "Metric": "Frequency",
                        "Outcome": "581"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS2"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "59%",
                        "581"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR2DS3",
                        "Value": "40%",
                        "Metric": "Frequency",
                        "Outcome": "401"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS3"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "40%",
                        "401"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR2DS4",
                        "Value": "100%",
                        "Metric": "Frequency",
                        "Outcome": "993"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS4"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR2DS5",
                        "Value": "28%",
                        "Metric": "Frequency",
                        "Outcome": "281"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS5"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "28%",
                        "281"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR3DL1",
                        "Value": "94%",
                        "Metric": "Frequency",
                        "Outcome": "929"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DL1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "94%",
                        "929"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR3DL2",
                        "Value": "100%",
                        "Metric": "Frequency",
                        "Outcome": "993"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DL2"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR3DL3",
                        "Value": "100%",
                        "Metric": "Frequency",
                        "Outcome": "993"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DL3"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "KIR": "KIR3DS1",
                        "Value": "36%",
                        "Metric": "Frequency",
                        "Outcome": "354"
                    },
                    "measures": "[N, % Positive]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DS1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "36%",
                        "354"
                    ]
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 18,
        "total_ground_truth_claims": 16,
        "number_of_matches": 16
    },
    "PMC9077443_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Overall",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "Events per total PY in cabotegravir group": "4/1956 (0\u00b720%)",
                        "Events per total PY in TDF-FTC group": "36/1942 (1\u00b785%)",
                        "HR (hazard ratio)": "0\u00b712 (0\u00b705\u20130\u00b731)",
                        "p value": "<0\u00b70001",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0\u00b712]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Overall",
                        "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                        "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                        "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.12, 0.05-0.31, <0.0001]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Age",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "HR (hazard ratio)": ".",
                        "p value": "0\u00b753",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age <25 years",
                        "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                        "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.17, 0.05-0.54, 0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Age",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "HR (hazard ratio)": ".",
                        "p value": "0\u00b753",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age \u226525 years",
                        "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                        "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.09, 0.02-0.49]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Age",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "HR (hazard ratio)": ".",
                        "p value": "0\u00b753",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "DMPA contraceptive method",
                        "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.05-0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Age",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "HR (hazard ratio)": ".",
                        "p value": "0\u00b753",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "NET-EN contraceptive method",
                        "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.22, 0.03-1.48]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Age",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "HR (hazard ratio)": ".",
                        "p value": "0\u00b753",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Implant contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.06, 0.00-1.16]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Age",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "HR (hazard ratio)": ".",
                        "p value": "0\u00b753",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Other contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.32, 0.01-9.89]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Age",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "HR (hazard ratio)": ".",
                        "p value": "0\u00b753",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI \u226430 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                        "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.06-0.45]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Age",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "HR (hazard ratio)": ".",
                        "p value": "0\u00b753",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI >30 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.05, 0.00-0.96]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Age <25 years",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "Events per total PY in cabotegravir group": "3/866 (0\u00b735%)",
                        "Events per total PY in TDF-FTC group": "20/851 (2\u00b734%)",
                        "HR (hazard ratio)": "0\u00b717 (0\u00b705\u20130\u00b754)",
                        "p value": ".",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0\u00b717]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age <25 years",
                        "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                        "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.17, 0.05-0.54, 0.53]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Age \u226525 years",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "Events per total PY in cabotegravir group": "1/1090 (0\u00b709%)",
                        "Events per total PY in TDF-FTC group": "16/1091 (1\u00b747%)",
                        "HR (hazard ratio)": "0\u00b709 (0\u00b702\u20130\u00b749)",
                        "p value": ".",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0\u00b709]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age \u226525 years",
                        "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                        "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.09, 0.02-0.49]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Contraceptive method",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "HR (hazard ratio)": ".",
                        "p value": "0\u00b787",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "DMPA contraceptive method",
                        "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.05-0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Contraceptive method",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "HR (hazard ratio)": ".",
                        "p value": "0\u00b787",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "NET-EN contraceptive method",
                        "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.22, 0.03-1.48]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Contraceptive method",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "HR (hazard ratio)": ".",
                        "p value": "0\u00b787",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Implant contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.06, 0.00-1.16]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Contraceptive method",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "HR (hazard ratio)": ".",
                        "p value": "0\u00b787",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Other contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.32, 0.01-9.89]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Contraceptive method",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "HR (hazard ratio)": ".",
                        "p value": "0\u00b787",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI \u226430 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                        "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.06-0.45]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Contraceptive method",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "HR (hazard ratio)": ".",
                        "p value": "0\u00b787",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI >30 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.05, 0.00-0.96]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Contraceptive method DMPA",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "Events per total PY in cabotegravir group": "3/1009 (0\u00b730%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2\u00b710%)",
                        "HR (hazard ratio)": "0\u00b716 (0\u00b705\u20130\u00b753)",
                        "p value": ".",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0\u00b716]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "DMPA contraceptive method",
                        "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.05-0.53]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Contraceptive method NET-EN",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "Events per total PY in cabotegravir group": "1/175 (0\u00b757%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3\u00b730%)",
                        "HR (hazard ratio)": "0\u00b722 (0\u00b703\u20131\u00b748)",
                        "p value": ".",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0\u00b722]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "NET-EN contraceptive method",
                        "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.22, 0.03-1.48]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Contraceptive method Implant",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "8/607 (1\u00b732%)",
                        "HR (hazard ratio)": "0\u00b706 (0\u00b700\u20131\u00b716)",
                        "p value": ".",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0\u00b706]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Implant contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.06, 0.00-1.16]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Contraceptive method Other",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "1/152 (0\u00b766%)",
                        "HR (hazard ratio)": "0\u00b732 (0\u00b701\u20139\u00b789)",
                        "p value": ".",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0\u00b732]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Other contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.32, 0.01-9.89]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Body-mass index \u226430 kg/m<sup>2</sup>",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "Events per total PY in cabotegravir group": "4/1389 (0\u00b729%)",
                        "Events per total PY in TDF-FTC group": "27/1447 (1\u00b787%)",
                        "HR (hazard ratio)": "0\u00b716 (0\u00b706\u20130\u00b745)",
                        "p value": "0\u00b747",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0\u00b716]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI \u226430 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                        "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.06-0.45]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Body-mass index >30 kg/m<sup>2</sup>",
                        "Intervention": "Cabotegravir",
                        "Comparator": "TDF-FTC (tenofovir disoproxil fumarate plus emtricitabine)",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "9/495 (1\u00b782%)",
                        "HR (hazard ratio)": "0\u00b705 (0\u00b700\u20130\u00b796)",
                        "p value": ".",
                        "Endpoint": "HIV incidence",
                        "Analysis": "ITT",
                        "Dataset": "40 HIV infections"
                    },
                    "measures": "[HR]",
                    "outcomes": "[0\u00b705]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI >30 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.05, 0.00-0.96]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 11,
        "total_ground_truth_claims": 9,
        "number_of_matches": 9
    },
    "PMC10294491_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Citation": "The trial was expected to generate approximately 72 endpoints per arm, but the observed HIV incidence was much lower, with only 11 and 6 incident HIV infections in the TDF-FTC and TAF-FTC arms, respectively",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[11, 6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.251, REF]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Citation": "The trial was expected to generate approximately 72 endpoints per arm, but the observed HIV incidence was much lower, with only 11 and 6 incident HIV infections in the TDF-FTC and TAF-FTC arms, respectively",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[11, 6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.137, 0.55 (0.20\u20131.48)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Citation": "The trial was expected to generate approximately 72 endpoints per arm, but the observed HIV incidence was much lower, with only 11 and 6 incident HIV infections in the TDF-FTC and TAF-FTC arms, respectively",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[11, 6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TDF/FTC",
                        "PYFU": "4386",
                        "Observed infections": "11",
                        "Predicted infections": "90.4",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[79.4, REF]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Citation": "The trial was expected to generate approximately 72 endpoints per arm, but the observed HIV incidence was much lower, with only 11 and 6 incident HIV infections in the TDF-FTC and TAF-FTC arms, respectively",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[11, 6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TAF/FTC",
                        "PYFU": "4370",
                        "Observed infections": "6",
                        "Predicted infections": "90.0",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[84.0, 1.06 (0.96-1.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Incidence rate (per 100 PYFU)": "0.251",
                        "Rate ratio (95% CI)": "REF",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.251, REF]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Incidence rate (per 100 PYFU)": "0.251",
                        "Rate ratio (95% CI)": "REF",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.137, 0.55 (0.20\u20131.48)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Incidence rate (per 100 PYFU)": "0.251",
                        "Rate ratio (95% CI)": "REF",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TDF/FTC",
                        "PYFU": "4386",
                        "Observed infections": "11",
                        "Predicted infections": "90.4",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[79.4, REF]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Incidence rate (per 100 PYFU)": "0.251",
                        "Rate ratio (95% CI)": "REF",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TAF/FTC",
                        "PYFU": "4370",
                        "Observed infections": "6",
                        "Predicted infections": "90.0",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[84.0, 1.06 (0.96-1.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Incidence rate (per 100 PYFU)": "0.251",
                        "Rate ratio (95% CI)": "REF",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incidence rate (per 100 PYFU)]",
                    "outcomes": "[0.251]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.251, REF]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Incidence rate (per 100 PYFU)": "0.251",
                        "Rate ratio (95% CI)": "REF",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incidence rate (per 100 PYFU)]",
                    "outcomes": "[0.251]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.137, 0.55 (0.20\u20131.48)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Incidence rate (per 100 PYFU)": "0.251",
                        "Rate ratio (95% CI)": "REF",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incidence rate (per 100 PYFU)]",
                    "outcomes": "[0.251]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TDF/FTC",
                        "PYFU": "4386",
                        "Observed infections": "11",
                        "Predicted infections": "90.4",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[79.4, REF]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Incidence rate (per 100 PYFU)": "0.251",
                        "Rate ratio (95% CI)": "REF",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incidence rate (per 100 PYFU)]",
                    "outcomes": "[0.251]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TAF/FTC",
                        "PYFU": "4370",
                        "Observed infections": "6",
                        "Predicted infections": "90.0",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[84.0, 1.06 (0.96-1.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Incidence rate (per 100 PYFU)": "0.137",
                        "Rate ratio (95% CI)": "0.55 (0.20, 1.48)",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.251, REF]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Incidence rate (per 100 PYFU)": "0.137",
                        "Rate ratio (95% CI)": "0.55 (0.20, 1.48)",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.137, 0.55 (0.20\u20131.48)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Incidence rate (per 100 PYFU)": "0.137",
                        "Rate ratio (95% CI)": "0.55 (0.20, 1.48)",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TDF/FTC",
                        "PYFU": "4386",
                        "Observed infections": "11",
                        "Predicted infections": "90.4",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[79.4, REF]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Incidence rate (per 100 PYFU)": "0.137",
                        "Rate ratio (95% CI)": "0.55 (0.20, 1.48)",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TAF/FTC",
                        "PYFU": "4370",
                        "Observed infections": "6",
                        "Predicted infections": "90.0",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[84.0, 1.06 (0.96-1.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Incidence rate (per 100 PYFU)": "0.137",
                        "Rate ratio (95% CI)": "0.55 (0.20, 1.48)",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incidence rate (per 100 PYFU)]",
                    "outcomes": "[0.137]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.251, REF]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Incidence rate (per 100 PYFU)": "0.137",
                        "Rate ratio (95% CI)": "0.55 (0.20, 1.48)",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incidence rate (per 100 PYFU)]",
                    "outcomes": "[0.137]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.137, 0.55 (0.20\u20131.48)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Incidence rate (per 100 PYFU)": "0.137",
                        "Rate ratio (95% CI)": "0.55 (0.20, 1.48)",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incidence rate (per 100 PYFU)]",
                    "outcomes": "[0.137]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TDF/FTC",
                        "PYFU": "4386",
                        "Observed infections": "11",
                        "Predicted infections": "90.4",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[79.4, REF]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Incidence rate (per 100 PYFU)": "0.137",
                        "Rate ratio (95% CI)": "0.55 (0.20, 1.48)",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[Incidence rate (per 100 PYFU)]",
                    "outcomes": "[0.137]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TAF/FTC",
                        "PYFU": "4370",
                        "Observed infections": "6",
                        "Predicted infections": "90.0",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[84.0, 1.06 (0.96-1.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Caption": "DISCOVER trial: primary outcome analysis",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.251, REF]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Caption": "DISCOVER trial: primary outcome analysis",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.137, 0.55 (0.20\u20131.48)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Caption": "DISCOVER trial: primary outcome analysis",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TDF/FTC",
                        "PYFU": "4386",
                        "Observed infections": "11",
                        "Predicted infections": "90.4",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[79.4, REF]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Caption": "DISCOVER trial: primary outcome analysis",
                        "Trial": "DISCOVER",
                        "Primary outcome analysis": "Yes"
                    },
                    "measures": "[Incident HIV infections]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TAF/FTC",
                        "PYFU": "4370",
                        "Observed infections": "6",
                        "Predicted infections": "90.0",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[84.0, 1.06 (0.96-1.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Footnote": "a Applying counterfactual placebo incidence rate of 2.06 per 100 PYFU (lower 2.5% credibility limit)",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.251, REF]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Footnote": "a Applying counterfactual placebo incidence rate of 2.06 per 100 PYFU (lower 2.5% credibility limit)",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.137, 0.55 (0.20\u20131.48)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Footnote": "a Applying counterfactual placebo incidence rate of 2.06 per 100 PYFU (lower 2.5% credibility limit)",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TDF/FTC",
                        "PYFU": "4386",
                        "Observed infections": "11",
                        "Predicted infections": "90.4",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[79.4, REF]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Footnote": "a Applying counterfactual placebo incidence rate of 2.06 per 100 PYFU (lower 2.5% credibility limit)",
                        "Counterfactual placebo incidence rate (per 100 PYFU)": "2.06",
                        "Credibility limit": "lower 2.5%"
                    },
                    "measures": "[]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TAF/FTC",
                        "PYFU": "4370",
                        "Observed infections": "6",
                        "Predicted infections": "90.0",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[84.0, 1.06 (0.96-1.17)]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 7,
        "total_ground_truth_claims": 4,
        "number_of_matches": 0
    },
    "PMC6158807_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[Rate per 100 person-year]",
                    "outcomes": "[3.02]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Composite endpoint (all participants)",
                        "Sample size": "692",
                        "No. of events": "123",
                        "Person-years of follow-up": "4071",
                        "Method": "Event rate across total follow-up"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[3.02 (2.53\u20133.61)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[Rate per 100 person-year CI lower bound]",
                    "outcomes": "[2.53]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[Rate per 100 person-year CI lower bound]",
                    "outcomes": "[2.53]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[Rate per 100 person-year CI lower bound]",
                    "outcomes": "[2.53]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[Rate per 100 person-year CI upper bound]",
                    "outcomes": "[3.61]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[Rate per 100 person-year CI upper bound]",
                    "outcomes": "[3.61]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[Rate per 100 person-year CI upper bound]",
                    "outcomes": "[3.61]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio]",
                    "outcomes": "[Current]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio]",
                    "outcomes": "[Current]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio]",
                    "outcomes": "[Current]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[p-value]",
                    "outcomes": "[< 0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[p-value]",
                    "outcomes": "[< 0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[p-value]",
                    "outcomes": "[< 0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[Cutoffs]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[Cutoffs]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[Cutoffs]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[Incidence rate]",
                    "outcomes": "[3.02]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[Incidence rate]",
                    "outcomes": "[3.02]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[Incidence rate]",
                    "outcomes": "[3.02]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[95% CI]",
                    "outcomes": "[2.53, 3.61]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[95% CI]",
                    "outcomes": "[2.53, 3.61]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[95% CI]",
                    "outcomes": "[2.53, 3.61]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range category range category]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Endpoint": "Composite endpoint",
                        "n": "692",
                        "No. of event": "123",
                        "Person-year of follow-up": "4071",
                        "Rate per 100 person-year": "95% CI, 3.02 (2.53\u20133.61)",
                        "CD4/CD8 ratio": "Current",
                        "p-value": "< 0.001"
                    },
                    "measures": "[CD4/CD8 ratio category range category range category range category range category range category range category range]",
                    "outcomes": "[< 0.3, 0.30\u20130.45, > 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 25,
        "total_ground_truth_claims": 4,
        "number_of_matches": 1
    },
    "PMC7522205_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[139, 117\u2013161, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[113, 86\u2013140, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[94, 73\u2013115, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[80, 65\u201395, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[87, 46\u2013128, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Total",
                        "Patients": "no. (%), 2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[72, 37\u2013107, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "no. (%), 1687 (59.3)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient]",
                    "outcomes": "[0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "no. (%), 254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient]",
                    "outcomes": [
                        "[139]",
                        "[95% CI]",
                        "[(117\u2013161)]",
                        "[P-value]",
                        "[<0.001]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "no. (%), 254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient]",
                    "outcomes": [
                        "[139]",
                        "[95% CI]",
                        "[(117\u2013161)]",
                        "[P-value]",
                        "[<0.001]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[139, 117\u2013161, <0.001]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "no. (%), 728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient]",
                    "outcomes": [
                        "[94]",
                        "[95% CI]",
                        "[(73\u2013115)]",
                        "[P-value]",
                        "[<0.001]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "no. (%), 728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient]",
                    "outcomes": [
                        "[94]",
                        "[95% CI]",
                        "[(73\u2013115)]",
                        "[P-value]",
                        "[<0.001]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[113, 86\u2013140, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "no. (%), 728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient]",
                    "outcomes": [
                        "[94]",
                        "[95% CI]",
                        "[(73\u2013115)]",
                        "[P-value]",
                        "[<0.001]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[94, 73\u2013115, <0.001]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "no. (%), 176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient]",
                    "outcomes": [
                        "[87]",
                        "[95% CI]",
                        "[(46\u2013128)]",
                        "[P-value]",
                        "[<0.001]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "no. (%), 176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient]",
                    "outcomes": [
                        "[87]",
                        "[95% CI]",
                        "[(46\u2013128)]",
                        "[P-value]",
                        "[<0.001]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[113, 86\u2013140, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "no. (%), 176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient]",
                    "outcomes": [
                        "[87]",
                        "[95% CI]",
                        "[(46\u2013128)]",
                        "[P-value]",
                        "[<0.001]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[80, 65\u201395, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "no. (%), 176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    },
                    "measures": "[Unadjusted Coefficient]",
                    "outcomes": [
                        "[87]",
                        "[95% CI]",
                        "[(46\u2013128)]",
                        "[P-value]",
                        "[<0.001]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[87, 46\u2013128, <0.001]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "no. (%), 1687 (59.3)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient]",
                    "outcomes": [
                        "[0]",
                        "[95% CI]",
                        "[(\u2013)]",
                        "[P-value]",
                        "[(\u2013)]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "no. (%), 254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient]",
                    "outcomes": [
                        "[113]",
                        "[95% CI]",
                        "[(86\u2013140)]",
                        "[P-value]",
                        "[<0.001]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[113, 86\u2013140, <0.001]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "no. (%), 728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient]",
                    "outcomes": [
                        "[80]",
                        "[95% CI]",
                        "[(65\u201395)]",
                        "[P-value]",
                        "[<0.001]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[80, 65\u201395, <0.001]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "no. (%), 176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Dataset": "Newly diagnosed HIV patients",
                        "Study Context": "Effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "Adjustment Factors": "Age at diagnosis; Sex; Marital status; Ethnicity; Education level; Occupation; Transmission route; Year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient]",
                    "outcomes": [
                        "[72]",
                        "[95% CI]",
                        "[(37\u2013107)]",
                        "[P-value]",
                        "[<0.001]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[72, 37\u2013107, <0.001]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 9,
        "total_ground_truth_claims": 8,
        "number_of_matches": 8
    },
    "PMC7414801_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[381]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[114]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[382]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[115]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[73]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[44]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[26]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "As-randomized",
                        "Total participants": "382",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[330]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[HIV VL count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "HIV detection visit"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[331]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M3"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[99]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M6"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[64]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M9"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[40]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M12"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[25]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Analysis group": "Continuous use",
                        "Total participants": "331",
                        "Exclusion criteria": "Women infected at baseline and visits following ART initiation",
                        "Dataset": "HIV Seroconverter Data",
                        "Timepoint": "M15"
                    },
                    "measures": "[CD4 count]",
                    "outcomes": "[14]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 24,
        "total_ground_truth_claims": 30,
        "number_of_matches": 0
    },
    "PMC9624454_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "No. (%), 314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[30.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[CMV Viremia (%)]",
                    "outcomes": "[30.7%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "All children",
                        "No.": "1024",
                        "CMV Viremia": "No. (%), 314 (30.7)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 59 (5.8)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia \u2264 1000 IU/mL Percentage]",
                    "outcomes": "[5.8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.8%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "No. (%), 253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[29.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV unexposed",
                        "No.": "872",
                        "CMV Viremia": "No. (%), 253 (29.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 45 (5.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[29.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia (%)]",
                    "outcomes": "[29.0%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed",
                        "No.": "118",
                        "CMV Viremia": "No. (%), 45 (38.1)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 10 (8.5)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (2.0\u20132.9)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[38.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed",
                        "No.": "118",
                        "CMV Viremia": "No. (%), 45 (38.1)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 10 (8.5)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (2.0\u20132.9)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[38.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed",
                        "No.": "118",
                        "CMV Viremia": "No. (%), 45 (38.1)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 10 (8.5)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (2.0\u20132.9)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[38.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed",
                        "No.": "118",
                        "CMV Viremia": "No. (%), 45 (38.1)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 10 (8.5)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (2.0\u20132.9)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[38.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[38.1%, 0.061]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "No. (%), 36 (37.1)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 6 (6.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[37.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "No. (%), 36 (37.1)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 6 (6.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[37.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "No. (%), 36 (37.1)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 6 (6.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[37.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "No. (%), 36 (37.1)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 6 (6.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[37.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[8.5%, 0.18]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "No. (%), 36 (37.1)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 6 (6.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[37.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (2.0\u20132.9), 0.24]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV exposed uninfected",
                        "No.": "97",
                        "CMV Viremia": "No. (%), 36 (37.1)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 6 (6.2)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[37.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[37.1%, 0.088]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "No. (%), 6 (40.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 3 (20.0)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[40.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "No. (%), 6 (40.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 3 (20.0)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[40.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "No. (%), 6 (40.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 3 (20.0)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[40.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "No. (%), 6 (40.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 3 (20.0)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[40.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[8.5%, 0.18]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "No. (%), 6 (40.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 3 (20.0)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[40.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (2.0\u20132.9), 0.24]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "No. (%), 6 (40.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 3 (20.0)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[40.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[6.2%, 0.56]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "No. (%), 6 (40.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 3 (20.0)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[40.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (1.9\u20132.7), 0.74]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "No. (%), 6 (40.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 3 (20.0)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[40.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[40.0%, 0.39]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "No. (%), 6 (40.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 3 (20.0)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[40.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[20.0%, 0.015]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HIV Exposure": "HIV infected",
                        "No.": "15",
                        "CMV Viremia": "No. (%), 6 (40.0)",
                        "CMV Viremia \u2264 1000 IU/mL": "No. (%), 3 (20.0)",
                        "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                        "Dataset": "Hospitalized children",
                        "Stratification": "HIV exposure or infection",
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[40.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[3.2 (2.6\u20135.3), 0.012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Citations": "At hospital discharge, 314 children had detectable CMV viremia (31%), with 5.8% having CMV levels \u2264 1000 IU/mL (Table 2).",
                        "Caption": "CMV detection, high-level viremia, and median viral loads among hospitalized children, stratified by HIV exposure or infection."
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[31.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Citations": "At hospital discharge, 314 children had detectable CMV viremia (31%), with 5.8% having CMV levels \u2264 1000 IU/mL (Table 2).",
                        "Caption": "CMV detection, high-level viremia, and median viral loads among hospitalized children, stratified by HIV exposure or infection."
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[31.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Citations": "At hospital discharge, 314 children had detectable CMV viremia (31%), with 5.8% having CMV levels \u2264 1000 IU/mL (Table 2).",
                        "Caption": "CMV detection, high-level viremia, and median viral loads among hospitalized children, stratified by HIV exposure or infection."
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[31.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Citations": "At hospital discharge, 314 children had detectable CMV viremia (31%), with 5.8% having CMV levels \u2264 1000 IU/mL (Table 2).",
                        "Caption": "CMV detection, high-level viremia, and median viral loads among hospitalized children, stratified by HIV exposure or infection."
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[31.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[8.5%, 0.18]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Citations": "At hospital discharge, 314 children had detectable CMV viremia (31%), with 5.8% having CMV levels \u2264 1000 IU/mL (Table 2).",
                        "Caption": "CMV detection, high-level viremia, and median viral loads among hospitalized children, stratified by HIV exposure or infection."
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[31.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (2.0\u20132.9), 0.24]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Citations": "At hospital discharge, 314 children had detectable CMV viremia (31%), with 5.8% having CMV levels \u2264 1000 IU/mL (Table 2).",
                        "Caption": "CMV detection, high-level viremia, and median viral loads among hospitalized children, stratified by HIV exposure or infection."
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[31.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[6.2%, 0.56]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Citations": "At hospital discharge, 314 children had detectable CMV viremia (31%), with 5.8% having CMV levels \u2264 1000 IU/mL (Table 2).",
                        "Caption": "CMV detection, high-level viremia, and median viral loads among hospitalized children, stratified by HIV exposure or infection."
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[31.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (1.9\u20132.7), 0.74]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Citations": "At hospital discharge, 314 children had detectable CMV viremia (31%), with 5.8% having CMV levels \u2264 1000 IU/mL (Table 2).",
                        "Caption": "CMV detection, high-level viremia, and median viral loads among hospitalized children, stratified by HIV exposure or infection."
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[31.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[40.0%, 0.39]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Citations": "At hospital discharge, 314 children had detectable CMV viremia (31%), with 5.8% having CMV levels \u2264 1000 IU/mL (Table 2).",
                        "Caption": "CMV detection, high-level viremia, and median viral loads among hospitalized children, stratified by HIV exposure or infection."
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[31.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[20.0%, 0.015]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Citations": "At hospital discharge, 314 children had detectable CMV viremia (31%), with 5.8% having CMV levels \u2264 1000 IU/mL (Table 2).",
                        "Caption": "CMV detection, high-level viremia, and median viral loads among hospitalized children, stratified by HIV exposure or infection."
                    },
                    "measures": "[CMV Viremia Percentage]",
                    "outcomes": "[31.0]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[3.2 (2.6\u20135.3), 0.012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[None]",
                    "outcomes": "[None]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[None]",
                    "outcomes": "[None]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.2%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[None]",
                    "outcomes": "[None]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[None]",
                    "outcomes": "[None]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[8.5%, 0.18]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[None]",
                    "outcomes": "[None]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (2.0\u20132.9), 0.24]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[None]",
                    "outcomes": "[None]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[6.2%, 0.56]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[None]",
                    "outcomes": "[None]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (1.9\u20132.7), 0.74]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[None]",
                    "outcomes": "[None]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[40.0%, 0.39]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[None]",
                    "outcomes": "[None]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[20.0%, 0.015]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                        "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                        "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
                    },
                    "measures": "[None]",
                    "outcomes": "[None]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[3.2 (2.6\u20135.3), 0.012]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 8,
        "total_ground_truth_claims": 15,
        "number_of_matches": 5
    },
    "PMC4549947_4": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "executive function",
                        "Gender": "Females",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": "[1.3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "gender": "females",
                        "p-interaction": "0.35"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.3]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "executive function",
                        "Gender": "Males",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": [
                        "[3.5]",
                        "[Confidence Interval]",
                        "[1.5\u20135.5]",
                        "[p-value]",
                        "[0.008]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "gender": "males",
                        "p-interaction": "0.35"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[3.5, 1.5\u20135.5, 0.008]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Females",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": "[0.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Females",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": "[0.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[3.1, 2.3\u20133.5, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Females",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": "[0.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "context": "alcohol use"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Females",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": "[0.9]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "females",
                        "p-intraction": "0.013"
                    },
                    "measures": "[OR]",
                    "outcomes": "[0.9]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Males",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": [
                        "[1.8]",
                        "[Confidence Interval]",
                        "[1.2\u20132.9]",
                        "[p-value]",
                        "[0.01]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Males",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": [
                        "[1.8]",
                        "[Confidence Interval]",
                        "[1.2\u20132.9]",
                        "[p-value]",
                        "[0.01]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[3.1, 2.3\u20133.5, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Males",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": [
                        "[1.8]",
                        "[Confidence Interval]",
                        "[1.2\u20132.9]",
                        "[p-value]",
                        "[0.01]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "context": "alcohol use"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Males",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": [
                        "[1.8]",
                        "[Confidence Interval]",
                        "[1.2\u20132.9]",
                        "[p-value]",
                        "[0.01]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "males",
                        "p-interaction": "0.013"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.8, 1.2\u20132.9, 0.01]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": "[2.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": "[2.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[3.1, 2.3\u20133.5, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": "[2.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "context": "alcohol use"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": "[2.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": "[2.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": "[2.6]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "context": "alcohol use",
                        "p-interaction": "0.32"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.6, 1.4\u20132.4, 0.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": [
                        "[3.1]",
                        "[Confidence Interval]",
                        "[2.3\u20133.5]",
                        "[p-value]",
                        "[0.01]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": [
                        "[3.1]",
                        "[Confidence Interval]",
                        "[2.3\u20133.5]",
                        "[p-value]",
                        "[0.01]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[3.1, 2.3\u20133.5, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": [
                        "[3.1]",
                        "[Confidence Interval]",
                        "[2.3\u20133.5]",
                        "[p-value]",
                        "[0.01]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "context": "alcohol use"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": [
                        "[3.1]",
                        "[Confidence Interval]",
                        "[2.3\u20133.5]",
                        "[p-value]",
                        "[0.01]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": [
                        "[3.1]",
                        "[Confidence Interval]",
                        "[2.3\u20133.5]",
                        "[p-value]",
                        "[0.01]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[Odds Ratio]",
                    "outcomes": [
                        "[3.1]",
                        "[Confidence Interval]",
                        "[2.3\u20133.5]",
                        "[p-value]",
                        "[0.01]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "context": "alcohol use",
                        "p-interaction": "0.32"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.6, 1.4\u20132.4, 0.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[3.1, 2.3\u20133.5, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "context": "alcohol use"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "context": "alcohol use",
                        "p-interaction": "0.32"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.6, 1.4\u20132.4, 0.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[3.1, 2.3\u20133.5, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "context": "alcohol use"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "context": "alcohol use",
                        "p-interaction": "0.32"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.6, 1.4\u20132.4, 0.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.32]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.32]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[3.1, 2.3\u20133.5, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.32]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "context": "alcohol use"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.32]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.32]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Hispanics",
                        "Race/Ethnicity": "Hispanics",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.32]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "context": "alcohol use",
                        "p-interaction": "0.32"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.6, 1.4\u20132.4, 0.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.72]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.72]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[3.1, 2.3\u20133.5, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.72]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "context": "alcohol use"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.72]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "African American",
                        "Race/Ethnicity": "African American",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.72]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.5]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Females",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.013]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Females",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.013]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[3.1, 2.3\u20133.5, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Females",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.013]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "context": "alcohol use"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Females",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.013]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Females",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.013]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "context": "alcohol use",
                        "p-interaction": "0.32"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.6, 1.4\u20132.4, 0.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Males",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Males",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[3.1, 2.3\u20133.5, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Males",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "context": "alcohol use"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Males",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "DRD2",
                        "SNP": "rs6277",
                        "Phenotype": "cognitive flexibility",
                        "Gender": "Males",
                        "Race/Ethnicity": "Not specified",
                        "Alcohol use": "Not specified",
                        "Hardy\u2013Weinberg equilibrium": "Yes"
                    },
                    "measures": "[p-value interaction]",
                    "outcomes": "[0.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "context": "alcohol use",
                        "p-interaction": "0.32"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.6, 1.4\u20132.4, 0.03]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 12,
        "total_ground_truth_claims": 10,
        "number_of_matches": 5
    },
    "PMC6694514_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[12]",
                        "[Percentage of Total G3+ Events]",
                        "[30.0]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Hepatobiliary disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "12",
                        "30.0%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Hepatobiliary disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[15]",
                        "[Percentage of Total G3+ Events]",
                        "[25.0]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Hepatobiliary disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "15",
                        "25.0%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[7]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[7]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[7]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[7]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[7]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[7]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[7]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[7]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[21.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[21.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[21.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[21.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[21.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[21.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[21.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Respiratory and thoracic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[21.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[6]",
                        "[Percentage of Total G3+ Events]",
                        "[15.0]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[6]",
                        "[Percentage of Total G3+ Events]",
                        "[15.0]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[6]",
                        "[Percentage of Total G3+ Events]",
                        "[15.0]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[6]",
                        "[Percentage of Total G3+ Events]",
                        "[15.0]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[6]",
                        "[Percentage of Total G3+ Events]",
                        "[15.0]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[6]",
                        "[Percentage of Total G3+ Events]",
                        "[15.0]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[6]",
                        "[Percentage of Total G3+ Events]",
                        "[15.0]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[6]",
                        "[Percentage of Total G3+ Events]",
                        "[15.0]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[10]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[10]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[10]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[10]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[10]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[10]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[10]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Blood and lymphatic disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[10]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[5]",
                        "[Percentage of Total G3+ Events]",
                        "[8.3]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[5]",
                        "[Percentage of Total G3+ Events]",
                        "[8.3]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[5]",
                        "[Percentage of Total G3+ Events]",
                        "[8.3]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[5]",
                        "[Percentage of Total G3+ Events]",
                        "[8.3]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[5]",
                        "[Percentage of Total G3+ Events]",
                        "[8.3]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[5]",
                        "[Percentage of Total G3+ Events]",
                        "[8.3]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[5]",
                        "[Percentage of Total G3+ Events]",
                        "[8.3]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Infections and infestations",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[5]",
                        "[Percentage of Total G3+ Events]",
                        "[8.3]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[3]",
                        "[Percentage of Total G3+ Events]",
                        "[7.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[4]",
                        "[Percentage of Total G3+ Events]",
                        "[6.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[4]",
                        "[Percentage of Total G3+ Events]",
                        "[6.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[4]",
                        "[Percentage of Total G3+ Events]",
                        "[6.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[4]",
                        "[Percentage of Total G3+ Events]",
                        "[6.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[4]",
                        "[Percentage of Total G3+ Events]",
                        "[6.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[4]",
                        "[Percentage of Total G3+ Events]",
                        "[6.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[4]",
                        "[Percentage of Total G3+ Events]",
                        "[6.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Metabolism and nutrition disorders",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[4]",
                        "[Percentage of Total G3+ Events]",
                        "[6.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[9]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[9]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[9]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[9]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[9]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[9]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[9]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[9]",
                        "[Percentage of Total G3+ Events]",
                        "[17.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Adverse Event SOC": "Other",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[13]",
                        "[Percentage of Total G3+ Events]",
                        "[16.7]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[20]",
                        "[Percentage of Total G3+ Events]",
                        "[47.6]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[20]",
                        "[Percentage of Total G3+ Events]",
                        "[47.6]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[20]",
                        "[Percentage of Total G3+ Events]",
                        "[47.6]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[20]",
                        "[Percentage of Total G3+ Events]",
                        "[47.6]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[20]",
                        "[Percentage of Total G3+ Events]",
                        "[47.6]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[20]",
                        "[Percentage of Total G3+ Events]",
                        "[47.6]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[20]",
                        "[Percentage of Total G3+ Events]",
                        "[47.6]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[20]",
                        "[Percentage of Total G3+ Events]",
                        "[47.6]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[34]",
                        "[Percentage of Total G3+ Events]",
                        "[15.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[34]",
                        "[Percentage of Total G3+ Events]",
                        "[15.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[34]",
                        "[Percentage of Total G3+ Events]",
                        "[15.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[34]",
                        "[Percentage of Total G3+ Events]",
                        "[15.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[34]",
                        "[Percentage of Total G3+ Events]",
                        "[15.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[34]",
                        "[Percentage of Total G3+ Events]",
                        "[15.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[34]",
                        "[Percentage of Total G3+ Events]",
                        "[15.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Total Number of Grade 3 or 4 Adverse Events": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[34]",
                        "[Percentage of Total G3+ Events]",
                        "[15.5]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[11]",
                        "[Percentage of Total G3+ Events]",
                        "[26.2]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[11]",
                        "[Percentage of Total G3+ Events]",
                        "[26.2]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[11]",
                        "[Percentage of Total G3+ Events]",
                        "[26.2]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[11]",
                        "[Percentage of Total G3+ Events]",
                        "[26.2]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[11]",
                        "[Percentage of Total G3+ Events]",
                        "[26.2]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[11]",
                        "[Percentage of Total G3+ Events]",
                        "[26.2]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[11]",
                        "[Percentage of Total G3+ Events]",
                        "[26.2]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-positive",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[11]",
                        "[Percentage of Total G3+ Events]",
                        "[26.2]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[14]",
                        "[Percentage of Total G3+ Events]",
                        "[6.4]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[14]",
                        "[Percentage of Total G3+ Events]",
                        "[6.4]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[14]",
                        "[Percentage of Total G3+ Events]",
                        "[6.4]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[14]",
                        "[Percentage of Total G3+ Events]",
                        "[6.4]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[14]",
                        "[Percentage of Total G3+ Events]",
                        "[6.4]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[14]",
                        "[Percentage of Total G3+ Events]",
                        "[6.4]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[14]",
                        "[Percentage of Total G3+ Events]",
                        "[6.4]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "One or more grade 3 or 4 AE considered to be at least possibly related to treatment": "",
                        "HIV Status": "HIV-negative",
                        "Trial": "REMoxTB",
                        "Population": "Matched",
                        "Enrollment Phase": "Yes",
                        "Grade": "3 or 4"
                    },
                    "measures": "[Number of Events]",
                    "outcomes": [
                        "[14]",
                        "[Percentage of Total G3+ Events]",
                        "[6.4]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 16,
        "total_ground_truth_claims": 10,
        "number_of_matches": 2
    },
    "PMC6937831_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Cancer",
                        "Number of deaths": "7 (7%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": "Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "6",
                        "4%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Cancer",
                        "Number of deaths": "7 (7%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": "Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Other diseases",
                        "ARM classification": "CD4 ceel count lowen than 200 cells/mm2",
                        "NARD classification": "CD4 ceel count higher than 200 cells/mm2"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "10",
                        "8%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Cancer",
                        "Number of deaths": "7 (7%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": "Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "CVD"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "12",
                        "9%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Cancer",
                        "Number of deaths": "7 (7%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": "Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Hepatic/liver-related"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "34",
                        "24%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Cancer",
                        "Number of deaths": "7 (7%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": "Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "External death",
                        "Cause of death": "sudden death, including accident, overdose and suicide"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "78",
                        "55%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Cancer",
                        "Number of deaths": "7 (7%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": "Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Other diseases",
                        "ARM classification": "CD4 ceel count lowen than 200 cells/mm2",
                        "NARD classification": "CD4 ceel count higher than 200 cells/mm2"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "2",
                        "1%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Cancer",
                        "Number of deaths": "7 (7%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": "Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "8",
                        "3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Cancer",
                        "Number of deaths": "7 (7%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": "Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Opportunistic"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "241",
                        "96%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Other diseases",
                        "Number of deaths": "10 (8%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": "Unknown death categorized based on CD4 count within 6-months prior to the date of death. The CD4 cell count of lower than 200 cells/mm\u00b2 was categorized as ARM and otherwise as NARM"
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[10]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "6",
                        "4%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Other diseases",
                        "Number of deaths": "10 (8%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": "Unknown death categorized based on CD4 count within 6-months prior to the date of death. The CD4 cell count of lower than 200 cells/mm\u00b2 was categorized as ARM and otherwise as NARM"
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[10]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Other diseases",
                        "ARM classification": "CD4 ceel count lowen than 200 cells/mm2",
                        "NARD classification": "CD4 ceel count higher than 200 cells/mm2"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "10",
                        "8%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "CVD",
                        "Number of deaths": "12 (9%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "6",
                        "4%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "CVD",
                        "Number of deaths": "12 (9%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "CVD"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "12",
                        "9%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Hepatic/liver-related",
                        "Number of deaths": "34 (24%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "6",
                        "4%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Hepatic/liver-related",
                        "Number of deaths": "34 (24%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[34]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Hepatic/liver-related"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "34",
                        "24%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "External death",
                        "Number of deaths": "78 (55%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": "Sudden death, including accident, overdose, and suicide"
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[78]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "6",
                        "4%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "External death",
                        "Number of deaths": "78 (55%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": "Sudden death, including accident, overdose, and suicide"
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[78]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "External death",
                        "Cause of death": "sudden death, including accident, overdose and suicide"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "78",
                        "55%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Opportunistic",
                        "Number of deaths": "8 (3%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "6",
                        "4%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Opportunistic",
                        "Number of deaths": "8 (3%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Other diseases",
                        "ARM classification": "CD4 ceel count lowen than 200 cells/mm2",
                        "NARD classification": "CD4 ceel count higher than 200 cells/mm2"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "2",
                        "1%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Opportunistic",
                        "Number of deaths": "8 (3%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "8",
                        "3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Opportunistic",
                        "Number of deaths": "8 (3%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Opportunistic"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "241",
                        "96%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Other diseases",
                        "Number of deaths": "241 (96%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[241]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "6",
                        "4%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Other diseases",
                        "Number of deaths": "241 (96%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[241]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Other diseases",
                        "ARM classification": "CD4 ceel count lowen than 200 cells/mm2",
                        "NARD classification": "CD4 ceel count higher than 200 cells/mm2"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "2",
                        "1%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Other diseases",
                        "Number of deaths": "241 (96%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[241]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "8",
                        "3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Other diseases",
                        "Number of deaths": "241 (96%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[241]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Opportunistic"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "241",
                        "96%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Cancer",
                        "Number of deaths": "2 (1%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "6",
                        "4%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "Cancer",
                        "Number of deaths": "2 (1%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Other diseases",
                        "ARM classification": "CD4 ceel count lowen than 200 cells/mm2",
                        "NARD classification": "CD4 ceel count higher than 200 cells/mm2"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "2",
                        "1%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "AIDS-Related Death (ARD)",
                        "Number of deaths": "8 (3%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "6",
                        "4%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Death category": "Death category of individuals living with HIV",
                        "Cause": "AIDS-Related Death (ARD)",
                        "Number of deaths": "8 (3%)",
                        "Dataset": "Individuals living with HIV",
                        "Definition": ""
                    },
                    "measures": "[Number of deaths]",
                    "outcomes": "[8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "8",
                        "3%"
                    ]
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 9,
        "total_ground_truth_claims": 8,
        "number_of_matches": 7
    },
    "PMC8340029_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "Before access",
                        "Number of infections/person-years": "133/2860",
                        "Incidence": "4\u00b765%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[4\u00b765]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "Before access",
                        "data representation": "incidence",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "133",
                        "person-years": "2860",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[4.65%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "Before access",
                        "Number of infections/person-years": "133/2860",
                        "Incidence": "4\u00b765%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "Number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[2.16%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "Before access",
                        "Number of infections/person-years": "133/2860",
                        "Incidence": "4\u00b765%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, 95% CI, p value]",
                    "outcomes": "[0.45, 0.25-0.81, 0.0076]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "Before access",
                        "Number of infections/person-years": "133/2860",
                        "Incidence": "4\u00b765%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.45, (0.25-0.82), 0.0085]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "Before access",
                        "Number of infections/person-years": "133/2860",
                        "Incidence": "4\u00b765%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "Before access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "46",
                        "person-years": "919",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[5.00%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "Before access",
                        "Number of infections/person-years": "133/2860",
                        "Incidence": "4\u00b765%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[2.29%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "Before access",
                        "Number of infections/person-years": "133/2860",
                        "Incidence": "4\u00b765%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.44, (0.23-0.85), 0.015]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "Before access",
                        "Number of infections/person-years": "133/2860",
                        "Incidence": "4\u00b765%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.43, (0.22-0.83), 0.012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "After access",
                        "Number of infections/person-years": "12/556",
                        "Incidence": "2\u00b716%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[2\u00b716]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "Number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[2.16%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "After access",
                        "Number of infections/person-years": "12/556",
                        "Incidence": "2\u00b716%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, 95% CI, p value]",
                    "outcomes": "[0.45, 0.25-0.81, 0.0076]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "180 days before versus 180 days after on-site PrEP access",
                        "Condition": "Before access",
                        "Number of infections/person-years": "46/919",
                        "Incidence": "5\u00b700%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[5\u00b700]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.45, (0.25-0.82), 0.0085]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "180 days before versus 180 days after on-site PrEP access",
                        "Condition": "Before access",
                        "Number of infections/person-years": "46/919",
                        "Incidence": "5\u00b700%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[5\u00b700]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "Before access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "46",
                        "person-years": "919",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[5.00%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "180 days before versus 180 days after on-site PrEP access",
                        "Condition": "Before access",
                        "Number of infections/person-years": "46/919",
                        "Incidence": "5\u00b700%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.45, (0.25-0.82), 0.0085]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "180 days before versus 180 days after on-site PrEP access",
                        "Condition": "Before access",
                        "Number of infections/person-years": "46/919",
                        "Incidence": "5\u00b700%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[2.29%]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "180 days before versus 180 days after on-site PrEP access",
                        "Condition": "Before access",
                        "Number of infections/person-years": "46/919",
                        "Incidence": "5\u00b700%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.44, (0.23-0.85), 0.015]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "180 days before versus 180 days after on-site PrEP access",
                        "Condition": "Before access",
                        "Number of infections/person-years": "46/919",
                        "Incidence": "5\u00b700%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.43, (0.22-0.83), 0.012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "180 days before versus 180 days after on-site PrEP access",
                        "Condition": "After access",
                        "Number of infections/person-years": "11/481",
                        "Incidence": "2\u00b729%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[2\u00b729]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.45, (0.25-0.82), 0.0085]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "180 days before versus 180 days after on-site PrEP access",
                        "Condition": "After access",
                        "Number of infections/person-years": "11/481",
                        "Incidence": "2\u00b729%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[2\u00b729]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[2.29%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "180 days before versus 180 days after on-site PrEP access",
                        "Condition": "After access",
                        "Number of infections/person-years": "11/481",
                        "Incidence": "2\u00b729%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.45, (0.25-0.82), 0.0085]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "180 days before versus 180 days after on-site PrEP access",
                        "Condition": "After access",
                        "Number of infections/person-years": "11/481",
                        "Incidence": "2\u00b729%",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    }
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.44, (0.23-0.85), 0.015]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "Before access",
                        "Adjusted incidence rate ratio (95% CI)": "0\u00b745 (0\u00b725-0\u00b781)",
                        "p value": "0\u00b70085",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    },
                    "measures": "[Adjusted incidence rate ratio (95% CI)]",
                    "outcomes": "[0\u00b745 (0\u00b725-0\u00b781)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.45, (0.25-0.82), 0.0085]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "Before access",
                        "Adjusted incidence rate ratio (95% CI)": "0\u00b745 (0\u00b725-0\u00b781)",
                        "p value": "0\u00b70085",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    },
                    "measures": "[Adjusted incidence rate ratio (95% CI)]",
                    "outcomes": "[0\u00b745 (0\u00b725-0\u00b781)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.43, (0.22-0.83), 0.012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "Before access",
                        "p value": "0\u00b70085",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    },
                    "measures": "[p value]",
                    "outcomes": "[0\u00b70085]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.45, (0.25-0.82), 0.0085]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "Before access",
                        "p value": "0\u00b70085",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    },
                    "measures": "[p value]",
                    "outcomes": "[0\u00b70085]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.43, (0.22-0.83), 0.012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "After access",
                        "Adjusted incidence rate ratio (95% CI)": "0\u00b745 (0\u00b725-0\u00b782)",
                        "p value": "0\u00b70085",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    },
                    "measures": "[Adjusted incidence rate ratio (95% CI)]",
                    "outcomes": "[0\u00b745 (0\u00b725-0\u00b782)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.45, (0.25-0.82), 0.0085]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "Including study visits with on-site PrEP access",
                        "Condition": "After access",
                        "p value": "0\u00b70085",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    },
                    "measures": "[p value]",
                    "outcomes": "[0\u00b70085]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.43, (0.22-0.83), 0.012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "180 days before versus 180 days after on-site PrEP access",
                        "Condition": "Before access",
                        "Adjusted incidence rate ratio (95% CI)": "0\u00b744 (0\u00b723-0\u00b785)",
                        "p value": "0\u00b7012",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    },
                    "measures": "[Adjusted incidence rate ratio (95% CI)]",
                    "outcomes": "[0\u00b744 (0\u00b723-0\u00b785)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.43, (0.22-0.83), 0.012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "180 days before versus 180 days after on-site PrEP access",
                        "Condition": "Before access",
                        "p value": "0\u00b7012",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    },
                    "measures": "[p value]",
                    "outcomes": "[0\u00b7012]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.43, (0.22-0.83), 0.012]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Context": "180 days before versus 180 days after on-site PrEP access",
                        "Condition": "After access",
                        "Adjusted incidence rate ratio (95% CI)": "0\u00b743 (0\u00b722-0\u00b783)",
                        "p value": "0\u00b7012",
                        "Caption": "Effect of on-site PrEP access on HIV incidence",
                        "Footnote": "Data are n/person-years, incidence, rate ratio (95% CI), or p value. PrEP=pre-exposure prophylaxis. Adjusted for study site and randomisation group. Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)."
                    },
                    "measures": "[Adjusted incidence rate ratio (95% CI)]",
                    "outcomes": "[0\u00b743 (0\u00b722-0\u00b783)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.43, (0.22-0.83), 0.012]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 16,
        "total_ground_truth_claims": 8,
        "number_of_matches": 8
    },
    "PMC8391097_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "PrEP status": "Overall",
                        "HIV infections": "No./total No. of individuals, 91/13 861",
                        "Total follow-up": "person-years, 26 210",
                        "Incidence (95% CI)": "per 100 person-years, 0.35 (0.28-0.43)",
                        "Exclusion criteria": "Excludes individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage"
                    },
                    "measures": "[Incidence Rate]",
                    "outcomes": "[0.35]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Overall",
                        "HIV infections number": "91",
                        "Number of individuals": "13 861",
                        "total follow-up (person-years)": "26 210",
                        "incidence": "per 100 person-years",
                        "exclusion criteria": "Excludes individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage"
                    },
                    "measures": "[incidence rate, 95% CI]",
                    "outcomes": "[0.35 (0.28-0.43)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "PrEP status": "Linked but not prescribed PrEP",
                        "HIV infections": "No./total No. of individuals, 36/3013",
                        "Total follow-up": "person-years, 4119",
                        "Incidence (95% CI)": "per 100 person-years, 0.87 (0.63-1.21)"
                    },
                    "measures": "[Incidence Rate]",
                    "outcomes": "[0.87]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Linked but not prescribed PrEP",
                        "HIV infection number": "36",
                        "Total number of individuals": "3013",
                        "total follow-up (person-years)": "4119",
                        "incidence": "per 100 person-years"
                    },
                    "measures": "[incidence rate, 95% CI]",
                    "outcomes": "[0.87, (0.63-1.21)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "PrEP status": "Prescribed PrEP but did not initiate",
                        "HIV infections": "No./total No. of individuals, 13/811",
                        "Total follow-up": "person-years, 1226",
                        "Incidence (95% CI)": "per 100 person-years, 1.06 (0.62-1.83)"
                    },
                    "measures": "[Incidence Rate]",
                    "outcomes": "[1.06]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Prescribed PrEP but did not initiate",
                        "HIV infection number": "11",
                        "Total number of individuals": "811",
                        "total follow-up (person-years)": "1226",
                        "incidence": "per 100 person-years"
                    },
                    "measures": "[incidence rate, 95% CI]",
                    "outcomes": "[1.06, (0.62-1.83)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "PrEP status": "Discontinued but reinitiated PrEP",
                        "HIV infections": "No./total No. of individuals, 4/1082",
                        "Total follow-up": "person-years, 1420",
                        "Incidence (95% CI)": "per 100 person-years, 0.28 (0.11-0.75)"
                    },
                    "measures": "[Incidence Rate]",
                    "outcomes": "[0.28]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Discontinued but reinitiated PrEP",
                        "HIV infection number": "4",
                        "Total number of individuals": "1082",
                        "total follow-up (person-years)": "1420",
                        "incidence": "per 100 person-years"
                    },
                    "measures": "[incidence rate, 95% CI]",
                    "outcomes": "[0.28, (0.11-0.75)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "PrEP status": "Discontinued and did not reinitiate PrEP",
                        "HIV infections": "No./total No. of individuals, 38/2108",
                        "Total follow-up": "person-years, 2973",
                        "Incidence (95% CI)": "per 100 person-years, 1.28 (0.93-1.76)"
                    },
                    "measures": "[Incidence Rate]",
                    "outcomes": "[1.28]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Discontinued and did not reinitiate PrEP",
                        "HIV infection number": "38",
                        "Total number of individuals": "2108",
                        "total follow-up (person-years)": "2973",
                        "incidence": "per 100 person-years"
                    },
                    "measures": "[incidence rate, 95% CI]",
                    "outcomes": "[1.28, (0.93-1.76)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "PrEP status": "Persistent on PrEP",
                        "HIV infections": "No./total No. of individuals, 0/5367",
                        "Total follow-up": "person-years, 9139",
                        "Incidence (95% CI)": "per 100 person-years, 0.00 (0.00-0.04)"
                    },
                    "measures": "[Incidence Rate]",
                    "outcomes": "[0.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Persistent on PrEP",
                        "HIV infection number": "0",
                        "Total number of individuals": "5367",
                        "total follow-up(person-years)": "9139",
                        "incidence": "per 100 person-years",
                        "definition": "Persistent on PrEP refers to individuals who initiated and remained on PrEP throughout follow-up",
                        "confidence interval": "One-sided 97.5% upper CI"
                    },
                    "measures": "[incidence rate, 97.5% CI]",
                    "outcomes": "[0.00, (0.00-0.04)]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 13,
        "total_ground_truth_claims": 6,
        "number_of_matches": 6
    },
    "PMC8748440_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "ISG15",
                        "Analysis Type": "Univariable Cox Regression",
                        "Hub Gene Source": "WGCNA",
                        "Module": "Salmon Module 1",
                        "Hazard Ratio": "0.29",
                        "95% Confidence Interval": "0.11\u20130.81",
                        "p-value": "0.0091"
                    },
                    "measures": "[Hazard Ratio]",
                    "outcomes": "[0.29]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "ISG15",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.29, 0.11\u20130.81 0.0091]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "IFI6",
                        "Analysis Type": "Univariable Cox Regression",
                        "Hub Gene Source": "WGCNA",
                        "Module": "Salmon Module 1",
                        "Hazard Ratio": "0.18",
                        "95% Confidence Interval": "0.037\u20130.86",
                        "p-value": "0.014"
                    },
                    "measures": "[Hazard Ratio]",
                    "outcomes": "[0.18]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFI6",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.18, 0.037\u20130.86, 0.014]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "IFI44L",
                        "Analysis Type": "Univariable Cox Regression",
                        "Hub Gene Source": "WGCNA",
                        "Module": "Salmon Module 1",
                        "Hazard Ratio": "0.55",
                        "95% Confidence Interval": "0.27\u20131.1",
                        "p-value": "0.083"
                    },
                    "measures": "[Hazard Ratio]",
                    "outcomes": "[0.55]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFI44L",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.55, 0.27\u20131.1, 0.083]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "IFI44",
                        "Analysis Type": "Univariable Cox Regression",
                        "Hub Gene Source": "WGCNA",
                        "Module": "Salmon Module 1",
                        "Hazard Ratio": "0.23",
                        "95% Confidence Interval": "0.047\u20131.2",
                        "p-value": "0.045"
                    },
                    "measures": "[Hazard Ratio]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFI44",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.23, 0.047\u20131.2, 0.045]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "IFIT1",
                        "Analysis Type": "Univariable Cox Regression",
                        "Hub Gene Source": "WGCNA",
                        "Module": "Salmon Module 1",
                        "Hazard Ratio": "0.37",
                        "95% Confidence Interval": "0.12\u20131.1",
                        "p-value": "0.054"
                    },
                    "measures": "[Hazard Ratio]",
                    "outcomes": "[0.37]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFIT1",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.37, 0.12\u20131.1, 0.054]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "OAS3",
                        "Analysis Type": "Univariable Cox Regression",
                        "Hub Gene Source": "WGCNA",
                        "Module": "Salmon Module 1",
                        "Hazard Ratio": "0.52",
                        "95% Confidence Interval": "0.22\u20131.3",
                        "p-value": "0.15"
                    },
                    "measures": "[Hazard Ratio]",
                    "outcomes": "[0.52]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "OAS3",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.52, 0.22\u20131.3, 0.15]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "XAF1",
                        "Analysis Type": "Univariable Cox Regression",
                        "Hub Gene Source": "WGCNA",
                        "Module": "Salmon Module 1",
                        "Hazard Ratio": "0.3",
                        "95% Confidence Interval": "0.1\u20130.92",
                        "p-value": "0.027"
                    },
                    "measures": "[Hazard Ratio]",
                    "outcomes": "[0.3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "XAF1",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.3, 0.1\u20130.92, 0.027]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "TRIM25",
                        "Analysis Type": "Univariable Cox Regression",
                        "Hub Gene Source": "WGCNA",
                        "Module": "Salmon Module 1",
                        "Hazard Ratio": "0.074",
                        "95% Confidence Interval": "0.0068\u20130.8",
                        "p-value": "0.023"
                    },
                    "measures": "[Hazard Ratio]",
                    "outcomes": "[0.074]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "TRIM25",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.074, 0.0068\u20130.8, 0.023]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "CMPK2",
                        "Analysis Type": "Univariable Cox Regression",
                        "Hub Gene Source": "WGCNA",
                        "Module": "Salmon Module 1",
                        "Hazard Ratio": "0.23",
                        "95% Confidence Interval": "0.037\u20131.5",
                        "p-value": "0.074"
                    },
                    "measures": "[Hazard Ratio]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "CMPK2",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.23, 0.037\u20131.5, 0.074]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "RSAD2",
                        "Analysis Type": "Univariable Cox Regression",
                        "Hub Gene Source": "WGCNA",
                        "Module": "Salmon Module 1",
                        "Hazard Ratio": "0.2",
                        "95% Confidence Interval": "0.041\u20130.99",
                        "p-value": "0.032"
                    },
                    "measures": "[Hazard Ratio]",
                    "outcomes": "[0.2]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "RSAD2",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.2, 0.041\u20130.99, 0.032]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "EIF2AK2",
                        "Analysis Type": "Univariable Cox Regression",
                        "Hub Gene Source": "WGCNA",
                        "Module": "Salmon Module 1",
                        "Hazard Ratio": "0.54",
                        "95% Confidence Interval": "0.12\u20132.4",
                        "p-value": "0.42"
                    },
                    "measures": "[Hazard Ratio]",
                    "outcomes": "[0.54]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "EIF2AK2",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.54, 0.12\u20132.4, 0.42]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "USP18",
                        "Analysis Type": "Univariable Cox Regression",
                        "Hub Gene Source": "WGCNA",
                        "Module": "Salmon Module 1",
                        "Hazard Ratio": "0.23",
                        "95% Confidence Interval": "0.062\u20130.84",
                        "p-value": "0.022"
                    },
                    "measures": "[Hazard Ratio]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "USP18",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.23, 0.062\u20130.84, 0.022]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Gene": "HERC6",
                        "Analysis Type": "Univariable Cox Regression",
                        "Hub Gene Source": "WGCNA",
                        "Module": "Salmon Module 1",
                        "Hazard Ratio": "0.16",
                        "95% Confidence Interval": "0.019\u20131.3",
                        "p-value": "0.057"
                    },
                    "measures": "[Hazard Ratio]",
                    "outcomes": "[0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "HERC6",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.16, 0.019\u20131.3, 0.057]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 18,
        "total_ground_truth_claims": 13,
        "number_of_matches": 13
    },
    "PMC7615197_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Intention-to-treat population",
                        "Deaths (Dexamethasone)": "116/263",
                        "Deaths (Placebo)": "126/257",
                        "Method": "Cox proportional hazards model",
                        "Test for proportional hazards": "0.36"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value]",
                    "outcomes": "[0.85, 0.66-1.10, 0.22]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "I",
                        "Deaths (Dexamethasone)": "22/99",
                        "Deaths (Placebo)": "28/97",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.41-1.25, 0.24, 0.15, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "II",
                        "Deaths (Dexamethasone)": "60/125",
                        "Deaths (Placebo)": "68/126",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.82, 0.58-1.16, 0.27, 0.30, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Intention-to-treat population",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade I",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "22/99",
                        "No. of deaths (Placebo)": "28/97",
                        "Hazard ratio": "0.72",
                        "Confidence interval": "[0.41, 1.25]",
                        "P-value": "0.24",
                        "Test for proportional hazards": "0.15",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.41, 1.25]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.72]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "I",
                        "Deaths (Dexamethasone)": "22/99",
                        "Deaths (Placebo)": "28/97",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.41-1.25, 0.24, 0.15, 0.63]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade II",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "60/125",
                        "No. of deaths (Placebo)": "68/126",
                        "Hazard ratio": "0.82",
                        "Confidence interval": "[0.58, 1.16]",
                        "P-value": "0.27",
                        "Test for proportional hazards": "0.57",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.58, 1.16]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.82]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "II",
                        "Deaths (Dexamethasone)": "60/125",
                        "Deaths (Placebo)": "68/126",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.82, 0.58-1.16, 0.27, 0.30, 0.63]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "Modified MRC grade: Grade III",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "34/39",
                        "No. of deaths (Placebo)": "30/34",
                        "Hazard ratio": "1.11",
                        "Confidence interval": "[0.70, 1.77]",
                        "P-value": "0.65",
                        "Test for proportional hazards": "0.89",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.70, 1.77]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[1.11]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[Hazard ratio]",
                        "[0.85]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Population": "All",
                        "Treatment": "Dexamethasone vs. Placebo",
                        "No. of deaths (Dexamethasone)": "116/263",
                        "No. of deaths (Placebo)": "126/257",
                        "Hazard ratio": "0.85",
                        "Confidence interval": "[0.66, 1.10]",
                        "P-value": "0.22",
                        "Test for proportional hazards": "0.36",
                        "Endpoint": "Death from any cause over the first 12 months after randomization",
                        "Analysis method": "Cox proportional hazards regression model",
                        "Kaplan-Meier transformation": "Time transformation"
                    },
                    "measures": "[0.66, 1.10]",
                    "outcomes": [
                        "[P-value]",
                        "[0.22]"
                    ]
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 19,
        "total_ground_truth_claims": 20,
        "number_of_matches": 3
    },
    "PMC9008168_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Participants without HIV",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Incidence rate unit": "cases/1000 PY",
                        "Incidence rate 95% CI": "54.7\u201389.0",
                        "HR": "1.00",
                        "HR 95% CI": "Reference",
                        "Dataset size": "2144 participants at risk"
                    },
                    "measures": "[Unadjusted incidence rate]",
                    "outcomes": "[69.8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Participants without HIV",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Incidence rate unit": "cases/1000 PY",
                        "Incidence rate 95% CI": "54.7\u201389.0",
                        "HR": "1.00",
                        "HR 95% CI": "Reference",
                        "Dataset size": "2144 participants at risk"
                    },
                    "measures": "[Unadjusted incidence rate]",
                    "outcomes": "[69.8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Participants without HIV",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Incidence rate unit": "cases/1000 PY",
                        "Incidence rate 95% CI": "54.7\u201389.0",
                        "HR": "1.00",
                        "HR 95% CI": "Reference",
                        "Dataset size": "2144 participants at risk"
                    },
                    "measures": "[Unadjusted incidence rate]",
                    "outcomes": "[69.8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "Participants without HIV",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Incidence rate unit": "cases/1000 PY",
                        "Incidence rate 95% CI": "54.7\u201389.0",
                        "HR": "1.00",
                        "HR 95% CI": "Reference",
                        "Dataset size": "2144 participants at risk"
                    },
                    "measures": "[Unadjusted incidence rate]",
                    "outcomes": "[69.8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "People without HIV",
                        "Person-time": "937.23",
                        "Failures": "65",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[69.80, (54.74\u201389.01)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Incidence rate unit": "cases/1000 PY",
                        "Incidence rate 95% CI": "69.8\u201385.2",
                        "HR": "1.13",
                        "HR 95% CI": "0.79\u20131.63",
                        "Dataset size": "2144 participants at risk"
                    },
                    "measures": "[Unadjusted incidence rate]",
                    "outcomes": "[77.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Incidence rate unit": "cases/1000 PY",
                        "Incidence rate 95% CI": "69.8\u201385.2",
                        "HR": "1.13",
                        "HR 95% CI": "0.79\u20131.63",
                        "Dataset size": "2144 participants at risk"
                    },
                    "measures": "[Unadjusted incidence rate]",
                    "outcomes": "[77.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Incidence rate unit": "cases/1000 PY",
                        "Incidence rate 95% CI": "69.8\u201385.2",
                        "HR": "1.13",
                        "HR 95% CI": "0.79\u20131.63",
                        "Dataset size": "2144 participants at risk"
                    },
                    "measures": "[Unadjusted incidence rate]",
                    "outcomes": "[77.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Incidence rate unit": "cases/1000 PY",
                        "Incidence rate 95% CI": "54.0\u201399.6",
                        "HR": "1.77",
                        "HR 95% CI": "1.22\u20132.55",
                        "Dataset size": "2144 participants at risk"
                    },
                    "measures": "[Unadjusted incidence rate]",
                    "outcomes": "[73.3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Incidence rate unit": "cases/1000 PY",
                        "Incidence rate 95% CI": "54.0\u201399.6",
                        "HR": "1.77",
                        "HR 95% CI": "1.22\u20132.55",
                        "Dataset size": "2144 participants at risk"
                    },
                    "measures": "[Unadjusted incidence rate]",
                    "outcomes": "[73.3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Incidence rate unit": "cases/1000 PY",
                        "Incidence rate 95% CI": "54.0\u201399.6",
                        "HR": "1.77",
                        "HR 95% CI": "1.22\u20132.55",
                        "Dataset size": "2144 participants at risk"
                    },
                    "measures": "[Unadjusted incidence rate]",
                    "outcomes": "[73.3]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Incidence rate unit": "cases/1000 PY",
                        "Incidence rate 95% CI": "24.1\u201359.1",
                        "HR": "0.43",
                        "HR 95% CI": "0.27\u20130.70",
                        "Dataset size": "2144 participants at risk"
                    },
                    "measures": "[Unadjusted incidence rate]",
                    "outcomes": "[37.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Incidence rate unit": "cases/1000 PY",
                        "Incidence rate 95% CI": "24.1\u201359.1",
                        "HR": "0.43",
                        "HR 95% CI": "0.27\u20130.70",
                        "Dataset size": "2144 participants at risk"
                    },
                    "measures": "[Unadjusted incidence rate]",
                    "outcomes": "[37.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Incidence rate unit": "cases/1000 PY",
                        "Incidence rate 95% CI": "24.1\u201359.1",
                        "HR": "0.43",
                        "HR 95% CI": "0.27\u20130.70",
                        "Dataset size": "2144 participants at risk"
                    },
                    "measures": "[Unadjusted incidence rate]",
                    "outcomes": "[37.7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "All participants",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants": "2144",
                        "Number of participants with BMI \u226525 kg/m\u00b2": "516",
                        "Percentage of participants with BMI \u226525 kg/m\u00b2": "24.1%"
                    },
                    "measures": "[Number of participants with BMI \u226525 kg/m\u00b2]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "All participants",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants": "2144",
                        "Number of participants with BMI \u226525 kg/m\u00b2": "516",
                        "Percentage of participants with BMI \u226525 kg/m\u00b2": "24.1%"
                    },
                    "measures": "[Number of participants with BMI \u226525 kg/m\u00b2]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "All participants",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants": "2144",
                        "Number of participants with BMI \u226525 kg/m\u00b2": "516",
                        "Percentage of participants with BMI \u226525 kg/m\u00b2": "24.1%"
                    },
                    "measures": "[Number of participants with BMI \u226525 kg/m\u00b2]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants without HIV": "2144",
                        "Number of participants with HIV": "0",
                        "Percentage of participants with HIV": "0%"
                    },
                    "measures": "[Number of participants with HIV]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants without HIV": "2144",
                        "Number of participants with HIV": "0",
                        "Percentage of participants with HIV": "0%"
                    },
                    "measures": "[Number of participants with HIV]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants without HIV": "2144",
                        "Number of participants with HIV": "0",
                        "Percentage of participants with HIV": "0%"
                    },
                    "measures": "[Number of participants with HIV]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants on non-TLD ART": "0",
                        "Number of participants on TLD": "0",
                        "Number of participants on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants on non-TLD ART": "0",
                        "Number of participants on TLD": "0",
                        "Number of participants on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants on non-TLD ART": "0",
                        "Number of participants on TLD": "0",
                        "Number of participants on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants without HIV and on non-TLD ART": "0",
                        "Number of participants without HIV and on TLD": "0",
                        "Number of participants without HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants without HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants without HIV and on non-TLD ART": "0",
                        "Number of participants without HIV and on TLD": "0",
                        "Number of participants without HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants without HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants without HIV and on non-TLD ART": "0",
                        "Number of participants without HIV and on TLD": "0",
                        "Number of participants without HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants without HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Group": "HIV and ART status",
                        "Condition": "BMI \u226525 kg/m\u00b2",
                        "Number of participants with HIV and on non-TLD ART": "0",
                        "Number of participants with HIV and on TLD": "0",
                        "Number of participants with HIV and on ART na\u00efve": "0"
                    },
                    "measures": "[Number of participants with HIV and on ART]",
                    "outcomes": ""
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 37,
        "total_ground_truth_claims": 4,
        "number_of_matches": 1
    },
    "PMC6033411_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "16",
                        "total participants": "46 (23%)",
                        "clustered participants": "13 (22%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.84 (0.36\u20131.89), 0.67]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "17+",
                        "total participants": "85 (42.5%)",
                        "clustered participants": "24 (40.7%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.87 (0.43\u20131.76), 0.69]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "School grade",
                        "grade group": "8\u20139",
                        "total participants": "90 (45%)",
                        "clustered participants": "30 (50.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "School grade",
                        "grade group": "10\u201312",
                        "total participants": "110 (55%)",
                        "clustered participants": "29 (49.2%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.8 (0.43\u20131.52), 0.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": "<999",
                        "total participants": "61 (30.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": "10,000\u201399,000",
                        "total participants": "112 (56%)",
                        "clustered participants": "27 (45.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.56 (0.29\u20131.11), 0.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": ">100,000",
                        "total participants": "27 (12.5%)",
                        "clustered participants": "10 (16.9%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.04 (0.39\u20132.65), 0.93]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": ">500",
                        "total participants": "92 (46%)",
                        "clustered participants": "30 (50.9%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264500",
                        "total participants": "75 (37.5%)",
                        "clustered participants": "19 (32.2%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.70 (0.35\u20131.37), 0.31]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264250",
                        "total participants": "15 (7.5%)",
                        "clustered participants": "4 (6.8%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.75 (0.2\u20132.4), 0.65]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Major drug resistance mutation",
                        "mutation status": "No",
                        "total participants": "180 (90%)",
                        "clustered participants": "55 (93.2)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Major drug resistance mutation",
                        "mutation status": "Yes",
                        "total participants": "20 (10%)",
                        "clustered participants": "4 (6.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.57 (0.16\u20131.63), 0.33]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "HSV-2 infection",
                        "infection status": "No",
                        "total participants": "90 (45%)",
                        "clustered participants": "25 (42.4%)",
                        "footnote": "HSV-2 infection status was not available for 41 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "HSV-2 infection",
                        "infection status": "Yes",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "23 (39%)",
                        "footnote": "HSV-2 infection status was not available for 41 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.3 (0.65\u20132.57), 0.45]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Ever pregnant",
                        "pregnancy status": "No",
                        "total participants": "122 (61%)",
                        "clustered participants": "37 (62.7%)",
                        "footnote": "Pregnancy history was not available for 29 women"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Total number",
                        "N": "200",
                        "Clustered": "N = 59",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Ever pregnant",
                        "pregnancy status": "Yes",
                        "total participants": "49 (24.5%)",
                        "clustered participants": "15 (25.4%)",
                        "footnote": "Pregnancy history was not available for 29 women"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.01 (0.48\u20132.06), 0.971]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "16",
                        "total participants": "46 (23%)",
                        "clustered participants": "13 (22%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.84 (0.36\u20131.89), 0.67]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "17+",
                        "total participants": "85 (42.5%)",
                        "clustered participants": "24 (40.7%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.87 (0.43\u20131.76), 0.69]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "School grade",
                        "grade group": "8\u20139",
                        "total participants": "90 (45%)",
                        "clustered participants": "30 (50.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "School grade",
                        "grade group": "10\u201312",
                        "total participants": "110 (55%)",
                        "clustered participants": "29 (49.2%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.8 (0.43\u20131.52), 0.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": "<999",
                        "total participants": "61 (30.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": "10,000\u201399,000",
                        "total participants": "112 (56%)",
                        "clustered participants": "27 (45.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.56 (0.29\u20131.11), 0.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": ">100,000",
                        "total participants": "27 (12.5%)",
                        "clustered participants": "10 (16.9%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.04 (0.39\u20132.65), 0.93]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": ">500",
                        "total participants": "92 (46%)",
                        "clustered participants": "30 (50.9%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264500",
                        "total participants": "75 (37.5%)",
                        "clustered participants": "19 (32.2%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.70 (0.35\u20131.37), 0.31]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264250",
                        "total participants": "15 (7.5%)",
                        "clustered participants": "4 (6.8%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.75 (0.2\u20132.4), 0.65]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Major drug resistance mutation",
                        "mutation status": "No",
                        "total participants": "180 (90%)",
                        "clustered participants": "55 (93.2)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Major drug resistance mutation",
                        "mutation status": "Yes",
                        "total participants": "20 (10%)",
                        "clustered participants": "4 (6.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.57 (0.16\u20131.63), 0.33]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "HSV-2 infection",
                        "infection status": "No",
                        "total participants": "90 (45%)",
                        "clustered participants": "25 (42.4%)",
                        "footnote": "HSV-2 infection status was not available for 41 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "HSV-2 infection",
                        "infection status": "Yes",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "23 (39%)",
                        "footnote": "HSV-2 infection status was not available for 41 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.3 (0.65\u20132.57), 0.45]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Ever pregnant",
                        "pregnancy status": "No",
                        "total participants": "122 (61%)",
                        "clustered participants": "37 (62.7%)",
                        "footnote": "Pregnancy history was not available for 29 women"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Characteristic": "Odds ratio",
                        "95% CI": "Provided",
                        "P-value": "Provided",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Ever pregnant",
                        "pregnancy status": "Yes",
                        "total participants": "49 (24.5%)",
                        "clustered participants": "15 (25.4%)",
                        "footnote": "Pregnancy history was not available for 29 women"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.01 (0.48\u20132.06), 0.971]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "16",
                        "total participants": "46 (23%)",
                        "clustered participants": "13 (22%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.84 (0.36\u20131.89), 0.67]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "17+",
                        "total participants": "85 (42.5%)",
                        "clustered participants": "24 (40.7%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.87 (0.43\u20131.76), 0.69]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "School grade",
                        "grade group": "8\u20139",
                        "total participants": "90 (45%)",
                        "clustered participants": "30 (50.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "School grade",
                        "grade group": "10\u201312",
                        "total participants": "110 (55%)",
                        "clustered participants": "29 (49.2%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.8 (0.43\u20131.52), 0.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": "<999",
                        "total participants": "61 (30.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": "10,000\u201399,000",
                        "total participants": "112 (56%)",
                        "clustered participants": "27 (45.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.56 (0.29\u20131.11), 0.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": ">100,000",
                        "total participants": "27 (12.5%)",
                        "clustered participants": "10 (16.9%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.04 (0.39\u20132.65), 0.93]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": ">500",
                        "total participants": "92 (46%)",
                        "clustered participants": "30 (50.9%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264500",
                        "total participants": "75 (37.5%)",
                        "clustered participants": "19 (32.2%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.70 (0.35\u20131.37), 0.31]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264250",
                        "total participants": "15 (7.5%)",
                        "clustered participants": "4 (6.8%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.75 (0.2\u20132.4), 0.65]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Major drug resistance mutation",
                        "mutation status": "No",
                        "total participants": "180 (90%)",
                        "clustered participants": "55 (93.2)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Major drug resistance mutation",
                        "mutation status": "Yes",
                        "total participants": "20 (10%)",
                        "clustered participants": "4 (6.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.57 (0.16\u20131.63), 0.33]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "HSV-2 infection",
                        "infection status": "No",
                        "total participants": "90 (45%)",
                        "clustered participants": "25 (42.4%)",
                        "footnote": "HSV-2 infection status was not available for 41 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "HSV-2 infection",
                        "infection status": "Yes",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "23 (39%)",
                        "footnote": "HSV-2 infection status was not available for 41 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.3 (0.65\u20132.57), 0.45]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Ever pregnant",
                        "pregnancy status": "No",
                        "total participants": "122 (61%)",
                        "clustered participants": "37 (62.7%)",
                        "footnote": "Pregnancy history was not available for 29 women"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "15 and younger",
                        "Total number": "69",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Ever pregnant",
                        "pregnancy status": "Yes",
                        "total participants": "49 (24.5%)",
                        "clustered participants": "15 (25.4%)",
                        "footnote": "Pregnancy history was not available for 29 women"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.01 (0.48\u20132.06), 0.971]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "16",
                        "Total number": "46",
                        "Clustered": "13",
                        "Odds ratio": "0.84",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "16",
                        "Total number": "46",
                        "Clustered": "13",
                        "Odds ratio": "0.84",
                        "95% CI": "0.36\u20131.89",
                        "P-value": "0.67",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "16",
                        "total participants": "46 (23%)",
                        "clustered participants": "13 (22%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.84 (0.36\u20131.89), 0.67]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "17+",
                        "Total number": "85",
                        "Clustered": "24",
                        "Odds ratio": "0.87",
                        "95% CI": "0.43\u20131.76",
                        "P-value": "0.69",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.69]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Age": "17+",
                        "Total number": "85",
                        "Clustered": "24",
                        "Odds ratio": "0.87",
                        "95% CI": "0.43\u20131.76",
                        "P-value": "0.69",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.69]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "17+",
                        "total participants": "85 (42.5%)",
                        "clustered participants": "24 (40.7%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.87 (0.43\u20131.76), 0.69]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "School grade": "8\u20139",
                        "Total number": "90",
                        "Clustered": "30",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "School grade": "8\u20139",
                        "Total number": "90",
                        "Clustered": "30",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "School grade",
                        "grade group": "8\u20139",
                        "total participants": "90 (45%)",
                        "clustered participants": "30 (50.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "School grade": "10\u201312",
                        "Total number": "110",
                        "Clustered": "29",
                        "Odds ratio": "0.8",
                        "95% CI": "0.43\u20131.52",
                        "P-value": "0.5",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "School grade": "10\u201312",
                        "Total number": "110",
                        "Clustered": "29",
                        "Odds ratio": "0.8",
                        "95% CI": "0.43\u20131.52",
                        "P-value": "0.5",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "School grade",
                        "grade group": "10\u201312",
                        "total participants": "110 (55%)",
                        "clustered participants": "29 (49.2%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.8 (0.43\u20131.52), 0.5]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Household income": "<999",
                        "Total number": "61",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Household income": "<999",
                        "Total number": "61",
                        "Clustered": "22",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": "<999",
                        "total participants": "61 (30.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Household income": "10,000\u201399,000",
                        "Total number": "112",
                        "Clustered": "27",
                        "Odds ratio": "0.56",
                        "95% CI": "0.29\u20131.11",
                        "P-value": "0.1",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Household income": "10,000\u201399,000",
                        "Total number": "112",
                        "Clustered": "27",
                        "Odds ratio": "0.56",
                        "95% CI": "0.29\u20131.11",
                        "P-value": "0.1",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": "10,000\u201399,000",
                        "total participants": "112 (56%)",
                        "clustered participants": "27 (45.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.56 (0.29\u20131.11), 0.1]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Household income": ">100,000",
                        "Total number": "27",
                        "Clustered": "10",
                        "Odds ratio": "1.04",
                        "95% CI": "0.39\u20132.65",
                        "P-value": "0.93",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.93]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Household income": ">100,000",
                        "Total number": "27",
                        "Clustered": "10",
                        "Odds ratio": "1.04",
                        "95% CI": "0.39\u20132.65",
                        "P-value": "0.93",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.93]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": ">100,000",
                        "total participants": "27 (12.5%)",
                        "clustered participants": "10 (16.9%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.04 (0.39\u20132.65), 0.93]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": ">500",
                        "Total number": "92",
                        "Clustered": "30",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": ">500",
                        "Total number": "92",
                        "Clustered": "30",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": ">500",
                        "total participants": "92 (46%)",
                        "clustered participants": "30 (50.9%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": ">500",
                        "Total number": "92",
                        "Clustered": "30",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264500",
                        "total participants": "75 (37.5%)",
                        "clustered participants": "19 (32.2%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.70 (0.35\u20131.37), 0.31]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": ">500",
                        "Total number": "92",
                        "Clustered": "30",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264250",
                        "total participants": "15 (7.5%)",
                        "clustered participants": "4 (6.8%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.75 (0.2\u20132.4), 0.65]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": ">500",
                        "Total number": "92",
                        "Clustered": "30",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Major drug resistance mutation",
                        "mutation status": "No",
                        "total participants": "180 (90%)",
                        "clustered participants": "55 (93.2)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": ">500",
                        "Total number": "92",
                        "Clustered": "30",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Major drug resistance mutation",
                        "mutation status": "Yes",
                        "total participants": "20 (10%)",
                        "clustered participants": "4 (6.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.57 (0.16\u20131.63), 0.33]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": ">500",
                        "Total number": "92",
                        "Clustered": "30",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "HSV-2 infection",
                        "infection status": "No",
                        "total participants": "90 (45%)",
                        "clustered participants": "25 (42.4%)",
                        "footnote": "HSV-2 infection status was not available for 41 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": ">500",
                        "Total number": "92",
                        "Clustered": "30",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "HSV-2 infection",
                        "infection status": "Yes",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "23 (39%)",
                        "footnote": "HSV-2 infection status was not available for 41 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.3 (0.65\u20132.57), 0.45]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": ">500",
                        "Total number": "92",
                        "Clustered": "30",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Ever pregnant",
                        "pregnancy status": "No",
                        "total participants": "122 (61%)",
                        "clustered participants": "37 (62.7%)",
                        "footnote": "Pregnancy history was not available for 29 women"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": ">500",
                        "Total number": "92",
                        "Clustered": "30",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Ever pregnant",
                        "pregnancy status": "Yes",
                        "total participants": "49 (24.5%)",
                        "clustered participants": "15 (25.4%)",
                        "footnote": "Pregnancy history was not available for 29 women"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.01 (0.48\u20132.06), 0.971]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": "\u2264500",
                        "Total number": "75",
                        "Clustered": "19",
                        "Odds ratio": "0.70",
                        "95% CI": "0.35\u20131.37",
                        "P-value": "0.31",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.31]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": "\u2264500",
                        "Total number": "75",
                        "Clustered": "19",
                        "Odds ratio": "0.70",
                        "95% CI": "0.35\u20131.37",
                        "P-value": "0.31",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.31]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": ">500",
                        "total participants": "92 (46%)",
                        "clustered participants": "30 (50.9%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": "\u2264500",
                        "Total number": "75",
                        "Clustered": "19",
                        "Odds ratio": "0.70",
                        "95% CI": "0.35\u20131.37",
                        "P-value": "0.31",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.31]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264500",
                        "total participants": "75 (37.5%)",
                        "clustered participants": "19 (32.2%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.70 (0.35\u20131.37), 0.31]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": "\u2264250",
                        "Total number": "15",
                        "Clustered": "4",
                        "Odds ratio": "0.75",
                        "95% CI": "0.2\u20132.4",
                        "P-value": "0.65",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": "\u2264250",
                        "Total number": "15",
                        "Clustered": "4",
                        "Odds ratio": "0.75",
                        "95% CI": "0.2\u20132.4",
                        "P-value": "0.65",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": ">500",
                        "total participants": "92 (46%)",
                        "clustered participants": "30 (50.9%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "CD4 cell count": "\u2264250",
                        "Total number": "15",
                        "Clustered": "4",
                        "Odds ratio": "0.75",
                        "95% CI": "0.2\u20132.4",
                        "P-value": "0.65",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264250",
                        "total participants": "15 (7.5%)",
                        "clustered participants": "4 (6.8%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.75 (0.2\u20132.4), 0.65]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Major drug resistance mutation": "No",
                        "Total number": "180",
                        "Clustered": "55",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Major drug resistance mutation": "No",
                        "Total number": "180",
                        "Clustered": "55",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": ">500",
                        "total participants": "92 (46%)",
                        "clustered participants": "30 (50.9%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Major drug resistance mutation": "No",
                        "Total number": "180",
                        "Clustered": "55",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Major drug resistance mutation",
                        "mutation status": "No",
                        "total participants": "180 (90%)",
                        "clustered participants": "55 (93.2)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Major drug resistance mutation": "Yes",
                        "Total number": "20",
                        "Clustered": "4",
                        "Odds ratio": "0.57",
                        "95% CI": "0.16\u20131.63",
                        "P-value": "0.33",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Major drug resistance mutation": "Yes",
                        "Total number": "20",
                        "Clustered": "4",
                        "Odds ratio": "0.57",
                        "95% CI": "0.16\u20131.63",
                        "P-value": "0.33",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": ">500",
                        "total participants": "92 (46%)",
                        "clustered participants": "30 (50.9%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "Major drug resistance mutation": "Yes",
                        "Total number": "20",
                        "Clustered": "4",
                        "Odds ratio": "0.57",
                        "95% CI": "0.16\u20131.63",
                        "P-value": "0.33",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[0.33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Major drug resistance mutation",
                        "mutation status": "Yes",
                        "total participants": "20 (10%)",
                        "clustered participants": "4 (6.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.57 (0.16\u20131.63), 0.33]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HSV-2 infection": "No",
                        "Total number": "90",
                        "Clustered": "25",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HSV-2 infection": "No",
                        "Total number": "90",
                        "Clustered": "25",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": ">500",
                        "total participants": "92 (46%)",
                        "clustered participants": "30 (50.9%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "HSV-2 infection": "No",
                        "Total number": "90",
                        "Clustered": "25",
                        "Odds ratio": "1.0",
                        "95% CI": "Provided",
                        "P-value": "\u2026",
                        "Genetic distance threshold": "4.5%",
                        "Study participants": "200 HIV-infected",
                        "Context": "Associations between demographic and epidemiological characteristics",
                        "Footnote": "Pregnancy history was not available for 29 women",
                        "Abbreviation": "ref: reference"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "HSV-2 infection",
                        "infection status": "No",
                        "total participants": "90 (45%)",
                        "clustered participants": "25 (42.4%)",
                        "footnote": "HSV-2 infection status was not available for 41 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 16,
        "total_ground_truth_claims": 17,
        "number_of_matches": 12
    }
}